Methods of introducing nucleic acids into cellular DNA

ABSTRACT

A method of introducing a nucleic acid sequence into a cell is provided where the cell has impaired or inhibited or disrupted DnaG primase activity or impaired or inhibited or disrupted DnaB helicase activity, or larger or increased gaps or distance between Okazaki fragments or lowered or reduced frequency of Okazaki fragment initiation, or the cell has increased single stranded DNA (ssDNA) on the lagging strand of the replication fork including transforming the cell through recombination with a nucleic acid oligomer.

RELATED APPLICATIONS

This application is a continuation application which claims priority toU.S. patent application Ser. No. 13/954,351, filed on Jul. 30, 2013,which claims the benefit of Provisional application 61/677,375 and filedJul. 30, 2012 each of which are hereby incorporated by reference intheir entireties.

STATEMENT OF GOVERNMENT INTERESTS

This invention was made with government support under Department ofEnergy Genomes to Life Center grant number DE-FG02-02ER63445 andNational Institutes of Health grant number P50 HG005550. The Governmenthas certain rights in the invention.

FIELD

The present invention relates in general to methods of introducingmultiple nucleic acid sequences into one or more target cells.

BACKGROUND

High throughput genome engineering has been used to create organismswith designed genomes. See Smith, H. O., Hutchison, C. A., Pfannkoch, C.and Venter, J. C. (2003), Generating a synthetic genome by whole genomeassembly: phi X174 bacteriophage from synthetic oligonucleotides, Proc.Natl. Acad. Sci. U. S. A., 100, 15440-15445 and Gibson, D. G., Glass, J.I., Lartigue, C., Noskov, V. N., Chuang, R. Y., Algire, M. A., Benders,G. A., Montague, M. G., Ma, L., Moodie, M. M. et al. (2010), Creation ofa Bacterial Cell Controlled by a Chemically Synthesized Genome, Science,329, 52-56. Certain methods of genome engineering involvingrecombination are known. See Wang, H. H., Isaacs, F. J., Carr, P. A.,Sun, Z. Z., Xu, G., Forest, C. R. and Church, G. M. (2009), Programmingcells by multiplex genome engineering and accelerated evolution, Nature,460, 894-898; U.S. Pat. No. 8,153,432; See Carr, P. A., Wang, H. H.,Sterling, B., Isaacs, F. J., Lajoie, M. J., Xu, G., Church, G. M. andJacobson, J. M. (2012), Enhanced Multiplex Genome Engineering throughCooperative Oligonucleotide Co-selection. Nucleic Acids Res., 1-11;Zechner et al., Coordinated leading- and lagging-strand synthesis at theE. Coli DNA replication fork. II. Frequency of primer synthesis andefficiency of primer utilization control of Okazaki fragment size,Journal of Biological Chemistry, 267, 4045-4053 (1992). See Wang, H. H.,Kim, H., Cong, L., Jeong, J., Bang, D. and Church, G. M. (2012),Genome-scale promoter engineering by coselection MAGE, Nat Meth, 9,591-593. Such methods typically involve introducing exogenous DNA intothe genomes of dividing cells. Such methods can utilize phage λ Redβrecombinase, which binds to ssDNA oligos, protecting them from ssDNAexonucleases, and facilitating their annealing to the lagging strand ofthe replication fork. See Ellis, H. M., Yu, D. G., DiTizio, T. andCourt, D. L. (2001), High efficiency mutagenesis, repair, andengineering of chromosomal DNA using single-stranded oligonucleotides,Proc. Natl. Acad. Sci. U. S. A., 98, 6742-6746. Generating a heterogenicpopulation has been harnessed for directed evolution of biosyntheticpathways and extensive cycling toward isogenic populations has been usedto remove all 314 TAG stop codons in subsets across 32 E. coli strains.See Isaacs, F. J., Carr, P. A., Wang, H.H., Lajoie, M. J., Sterling, B.,Kraal, L., Tolonen, A. C., Gianoulis, T. A., Goodman, D. B., Reppas, N.B. et al. (2011), Precise manipulation of chromosomes in vivo enablesgenome-wide codon replacement, Science, 333, 348-353.

Several approaches are known for improving introduction of exogenousnucleic acids into the genome of a cell such as targeting oligos to thelagging strand of the replication fork, See Li, X. T., Costantino, N.,Lu, L. Y., Liu, D. P., Watt, R. M., Cheah, K. S., Court, D. L. andHuang, J. D. (2003), Identification of factors influencing strand biasin oligonucleotide-mediated recombination in Escherichia coli, NucleicAcids Res, 31, 6674-6687, evading mismatch repair using modifiednucleotides, See Wang, H. H., Xu, G., Vonner, A. J. and Church, G. M.(2011), Modified bases enable high-efficiency oligonucleotide-mediatedallelic replacement via mismatch repair evasion, Nucleic Acids Res, 39,7336-7347, minimizing oligo secondary structure and optimizing homologylengths, blocking oligo degradation with 5′ phosphorothioate bonds,avoiding sequences with high degrees of off-target homology elsewhere inthe genome, and removing the mismatch repair protein MutS to avoidreversion of mutated alleles. See Costantino, N. and Court, D. L.(2003), Enhanced levels of lambda Red-mediated recombinants in mismatchrepair mutants, Proc Natl Acad Sci U S A, 100, 15748-15753.

Okazaki Fragment (OF) size can be modulated by the frequency of OFprimer synthesis by DnaG primase. Tougu et al. have reported E. coliprimase variants with impaired helicase binding, resulting inless-frequent OF initiation, but normal replication fork rate, primingefficiency, and primer utilization during in vitro replication. Thesevariants, K580A and Q576A, resulted in in vitro OFs that wereapproximately 1.5- and 8-fold longer (respectively) than those initiatedby wild type (wt) DnaG. See Tougu, K. and Marians, K. J. (1996), TheExtreme C Terminus of Primase Is Required for Interaction with DnaB atthe Replication Fork, Journal of Biological Chemistry, 271, 21391-21397.

SUMMARY

Embodiments of the present disclosure are directed to methods forintroducing one or more exogenous nucleic acids into the DNA or genomeof a cell where the cell has impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity.Embodiments of the present disclosure are directed to methods forintroducing one or more exogenous nucleic acids into the DNA or genomeof a cell which has been genetically altered to impair or inhibit ordisrupt primase activity or impair or inhibit or disrupt helicaseactivity.

Embodiments of the present disclosure are directed to methods forintroducing a plurality of exogenous nucleic acids into the DNA of acell where the cell has impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity.Embodiments of the present disclosure are directed to methods forintroducing one or more exogenous nucleic acids into the DNA of a cellthrough recombination where the cell has impaired or inhibited ordisrupted primase activity or impaired or inhibited or disruptedhelicase activity. Embodiments of the present disclosure are directed tomethods for introducing a plurality of nucleic acids into the DNA of acell through recombination where the cell has impaired or inhibited ordisrupted primase activity or impaired or inhibited or disruptedhelicase activity.

Embodiments of the present disclosure include methods of disruptinginteraction between primase and helicase in a cell while introducing oneor more or a plurality of exogenous nucleic acids into the DNA of thecell. According to certain aspects, disrupting the interaction betweenprimase and helicase increases accessible exogenous ssDNA on a laggingstrand of a replication fork in the cell. According to certain aspects,disrupting the interaction between primase and helicase increasesaccessible exogenous ssDNA on a lagging strand of a replication fork inthe cell and increases allele replacement frequencies in transformationor transfection methods described herein.

According to one aspect, multiple nucleic acid sequences are introducedby recombination into a plurality of cells using a multiplex methodwhere a plurality of cells in a vessel receive multiple nucleic acidsinto their genomes through recombination and where the cells haveimpaired or inhibited or disrupted primase activity or impaired orinhibited or disrupted helicase activity. The cells can then be thesubject of further recombination of one or more exogenous nucleic acidsequences into their genomes, for example, by cyclic addition ofexogenous nucleic acids into cells in parallel, i.e. multiple cellsbeing subjected to recombination in a vessel. The addition of one ormore nucleic acids can be random or in a specific order or locationwithin the genome. The addition of one or more nucleic acids can be withor without use of one or more selectable markers.

Accordingly, embodiments of the present disclosure are directed to amethod including introducing one or more or a plurality of nucleic acidsequences (such as exogenous sequences) into a cell having impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity. Embodiments of the present disclosure arealso directed to a method including transforming or transfecting a cellhaving impaired or inhibited or disrupted primase activity or impairedor inhibited or disrupted helicase activity with one or more or aplurality of nucleic acid sequences. According to certain aspects, atransformed or transfected cell having impaired or inhibited ordisrupted primase activity or impaired or inhibited or disruptedhelicase activity which has one or more or a plurality of nucleic acidsequences inserted into its genome (for example by a process referred toas recombination), may be further transformed or transfected one or moretimes resulting in a cell having multiple exogeneous nucleic acidsequences in its genome.

According to one aspect, a method is provided including transforming ortransfecting a cell having impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity usingtransformation medium or transfection medium including at least onenucleic acid oligomer, replacing the transformation medium ortransfection medium with growth medium, incubating the cell in thegrowth medium, and repeating the steps of transforming or transfectingand incubating the cell in growth medium until multiple nucleic acidsequences have been introduced into the cell. In certain aspects, a poolof nucleic acid oligomers is added to the cell having impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity in the transformation or transfection step.In other aspects, an oligomer is single-stranded DNA. In other aspects,multiple mutations are generated in a chromosome or in a genome. Instill other aspects, the growth medium contains an antibiotic, and/orthe growth medium is minimal medium. In certain other aspects, aplurality of cells having impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity iscontacted with a nucleic acid oligomer in the transformation ortransfection step. In certain other aspects, a plurality of cells havingimpaired or inhibited or disrupted primase activity or impaired orinhibited or disrupted helicase activity is contacted with a pluralityof nucleic acid oligomers in the transformation or transfection step. Incertain other aspects, the cell or cells may be contained within avessel such as a microfuge tube, a test tube, a cuvette, a multi-wellplate, a microfiber, a flow system or other structures or systems knownto those of skill in the art for carrying out the transformation ortransfection of cells. According to certain aspects, the method may beautomated.

According to one aspect, a cell having impaired or inhibited ordisrupted primase activity is understood to mean that the primaseactivity in the cell is below that normally present in a wild type cellof the same type. According to one aspect, a cell having impaired orinhibited or disrupted primase activity is understood to mean that theprimase has a diminished interaction with helicase. According to oneaspect, a cell can be genetically modified to impair, inhibit or disruptprimase activity directly or indirectly. According to one aspect, thecell may still exhibit primase activity, but the primase activity hasbeen impaired, inhibited or disrupted compared to a wild type cell ofthe same type.

According to one aspect, a cell having impaired or inhibited ordisrupted helicase activity is understood to mean that the helicaseactivity in the cell is below that normally present in a wild type cellof the same type. According to one aspect, a cell having impaired orinhibited or disrupted helicase activity is understood to mean that thehelicase has a diminished interaction with primase. According to oneaspect, a cell can be genetically modified to impair, inhibit or disrupthelicase activity directly or indirectly. According to one aspect, thecell may still exhibit helicase activity, but the helicase activity hasbeen impaired, inhibited or disrupted compared to a wild type cell ofthe same type.

Embodiments of the present disclosure are directed to methods forintroducing one or more exogenous nucleic acids into the DNA or genomeof a cell where the cell has increased single stranded DNA (ssDNA) onthe lagging strand of the replication fork. Embodiments of the presentdisclosure are directed to methods for introducing one or more exogenousnucleic acids into the DNA or genome of a cell which has beengenetically altered to increase single stranded DNA (ssDNA) on thelagging strand of the replication fork.

According to one aspect, a cell having increased single stranded DNA(ssDNA) on the lagging strand of the replication fork is understood tomean that the amount or frequency of single stranded DNA (ssDNA) on thelagging strand of the replication fork is above that normally present ina wild type cell of the same type. According to one aspect, a cell canbe genetically modified to increase single stranded DNA (ssDNA) on thelagging strand of the replication fork.

Embodiments of the present disclosure are directed to methods forintroducing a plurality of exogenous nucleic acids into the DNA of acell where the cell has increased single stranded DNA (ssDNA) on thelagging strand of the replication fork or has been genetically alteredto increase single stranded DNA (ssDNA) on the lagging strand of thereplication fork. Embodiments of the present disclosure are directed tomethods for introducing one or more exogenous nucleic acids into the DNAof a cell through recombination where the cell has increased singlestranded DNA (ssDNA) on the lagging strand of the replication fork orhas been genetically altered to increase single stranded DNA (ssDNA) onthe lagging strand of the replication fork. Embodiments of the presentdisclosure are directed to methods for introducing a plurality ofnucleic acids into the DNA of a cell through recombination where thecell has increased single stranded DNA (ssDNA) on the lagging strand ofthe replication fork or has been genetically altered to increase singlestranded DNA (ssDNA) on the lagging strand of the replication fork.

Embodiments of the present disclosure include methods of increasingsingle stranded DNA (ssDNA) on the lagging strand of the replicationfork or genetically altering a cell to increase single stranded DNA(ssDNA) on the lagging strand of the replication fork while introducingone or more or a plurality of exogenous nucleic acids into the DNA ofthe cell. According to certain aspects, disrupting the interactionbetween primase and helicase such as by genetically altering a cell toimpair or inhibit primase activity or impair or inhibit helicaseactivity or both increases accessible exogenous ssDNA on a laggingstrand of a replication fork in the cell. According to certain aspects,disrupting the interaction between primase and helicase increasesaccessible exogenous ssDNA on a lagging strand of a replication fork inthe cell and increases allele replacement frequencies in transformationor transfection methods described herein.

According to one aspect, multiple nucleic acid sequences are introducedby recombination into a plurality of cells using a multiplex methodwhere a plurality of cells in a vessel receive multiple nucleic acidsinto their genomes through recombination and where the cells haveincreased single stranded DNA (ssDNA) on the lagging strand of thereplication fork or have been genetically altered to increase singlestranded DNA (ssDNA) on the lagging strand of the replication fork. Thecells can then be the subject of further recombination of one or moreexogenous nucleic acid sequences into their genomes, for example, bycyclic addition of exogenous nucleic acids into cells in parallel, i.e.multiple cells being subjected to recombination in a vessel. Theaddition of one or more nucleic acids can be random or in a specificorder or location within the genome. The addition of one or more nucleicacids can be with or without use of one or more selectable markers.

Accordingly, embodiments of the present disclosure are directed to amethod including introducing one or more or a plurality of nucleic acidsequences (such as exogenous sequences) into a cell having increasedsingle stranded DNA (ssDNA) on the lagging strand of the replicationfork or having been genetically altered to increase single stranded DNA(ssDNA) on the lagging strand of the replication fork. Embodiments ofthe present disclosure are also directed to a method includingtransforming or transfecting a cell having increased single stranded DNA(ssDNA) on the lagging strand of the replication fork or having beengenetically altered to increase single stranded DNA (ssDNA) on thelagging strand of the replication fork with one or more or a pluralityof nucleic acid sequences. According to certain aspects, a transformedor transfected cell having increased single stranded DNA (ssDNA) on thelagging strand of the replication fork or having been geneticallyaltered to increase single stranded DNA (ssDNA) on the lagging strand ofthe replication fork which has one or more or a plurality of nucleicacid sequences inserted into its genome (for example by a processreferred to as recombination), may be further transformed or transfectedone or more times resulting in a cell having multiple exogeneous nucleicacid sequences in its genome.

According to one aspect, a method is provided including transforming ortransfecting a cell having increased single stranded DNA (ssDNA) on thelagging strand of the replication fork or having been geneticallyaltered to increase single stranded DNA (ssDNA) on the lagging strand ofthe replication fork using transformation medium or transfection mediumincluding at least one nucleic acid oligomer, replacing thetransformation medium or transfection medium with growth medium,incubating the cell in the growth medium, and repeating the steps oftransforming or transfecting and incubating the cell in growth mediumuntil multiple nucleic acid sequences have been introduced into thecell. In certain aspects, a pool of nucleic acid oligomers is added tothe cell having increased single stranded DNA (ssDNA) on the laggingstrand of the replication fork or having been genetically altered toincrease single stranded DNA (ssDNA) on the lagging strand of thereplication fork in the transformation or transfection step. In otheraspects, an oligomer is single-stranded DNA. In other aspects, multiplemutations are generated in a chromosome or in a genome. In still otheraspects, the growth medium contains an antibiotic, and/or the growthmedium is minimal medium. In certain other aspects, a plurality of cellshaving increased single stranded DNA (ssDNA) on the lagging strand ofthe replication fork or having been genetically altered to increasesingle stranded DNA (ssDNA) on the lagging strand of the replicationfork is contacted with a nucleic acid oligomer in the transformation ortransfection step. In certain other aspects, a plurality of cells havingincreased single stranded DNA (ssDNA) on the lagging strand of thereplication fork or having been genetically altered to increase singlestranded DNA (ssDNA) on the lagging strand of the replication fork iscontacted with a plurality of nucleic acid oligomers in thetransformation or transfection step. In certain other aspects, the cellor cells may be contained within a vessel such as a microfuge tube, atest tube, a cuvette, a multi-well plate, a microfiber, a flow system orother structures or systems known to those of skill in the art forcarrying out the transformation or transfection of cells. According tocertain aspects, the method may be automated.

Embodiments of the present disclosure are directed to methods forintroducing one or more exogenous nucleic acids into the DNA or genomeof a cell modified to increase distance between Okazaki fragments, suchas nascent Okazaki fragments, or lower or reduce frequency of Okazakifragment initiation. Embodiments of the present disclosure are directedto methods for introducing one or more exogenous nucleic acids into theDNA or genome of a cell which has been genetically altered to increasedistance between Okazaki fragments or lower or reduce frequency ofOkazaki fragment initiation.

According to one aspect, a cell having increased distance betweenOkazaki fragments is understood to mean that the gaps or distancebetween Okazaki fragments is above that normally present in a wild typecell of the same type. According to one aspect, a cell can begenetically modified to increase gaps or distance between Okazakifragments.

According to one aspect, a cell having lowered or reduced frequency ofOkazaki fragment initiation is understood to mean that the frequency ofOkazaki fragment initiation is below that normally present in a wildtype cell of the same type. According to one aspect, a cell can begenetically modified to reduce or lower frequency of Okazaki fragmentinitiation.

Embodiments of the present disclosure are directed to methods forintroducing a plurality of exogenous nucleic acids into the DNA of acell where the cell exhibits larger or increased gaps or increaseddistance between Okazaki fragments or lowered or reduced frequency ofOkazaki fragment initiation. Embodiments of the present disclosure aredirected to methods for introducing one or more exogenous nucleic acidsinto the DNA of a cell through recombination where the cell hasincreased distance between Okazaki fragments or lowered or reducedfrequency of Okazaki fragment initiation. Embodiments of the presentdisclosure are directed to methods for introducing a plurality ofnucleic acids into the DNA of a cell through recombination where thecell has increased distance between Okazaki fragments or lowered orreduced frequency of Okazaki fragment initiation.

Embodiments of the present disclosure include methods of increasing gapsbetween Okazaki fragments or lowering or reducing frequency of Okazakifragment initiation while introducing one or more or a plurality ofexogenous nucleic acids into the DNA of the cell. According to certainaspects, disrupting the interaction between primase and helicase such asby genetically altering a cell to impair or inhibit primase activity orimpair or inhibit helicase activity or both increases gaps or distancebetween Okazaki fragments in the cell or lowers or reduces frequency ofOkazaki fragment initiation. According to certain aspects, disruptingthe interaction between primase and helicase increases distance betweenOkazaki fragments in the cell or lowers or reduces frequency of Okazakifragment initiation and increases allele replacement frequencies intransformation or transfection methods described herein.

According to one aspect, multiple nucleic acid sequences are introducedby recombination into a plurality of cells using a multiplex methodwhere a plurality of cells in a vessel receive multiple nucleic acidsinto their genomes through recombination and where the cells exhibitslarger or increased gaps or distance between Okazaki fragments orlowered or reduced frequency of Okazaki fragment initiation. The cellscan then be the subject of further recombination of one or moreexogenous nucleic acid sequences into their genomes, for example, bycyclic addition of exogenous nucleic acids into cells in parallel, i.e.multiple cells being subjected to recombination in a vessel. Theaddition of one or more nucleic acids can be random or in a specificorder or location within the genome. The addition of one or more nucleicacids can be with or without use of one or more selectable markers.

Accordingly, embodiments of the present disclosure are directed to amethod including introducing one or more or a plurality of nucleic acidsequences (such as exogenous sequences) into a cell exhibiting larger orincreased gaps or distance between Okazaki fragments or lowered orreduced frequency of Okazaki fragment initiation. Embodiments of thepresent disclosure are also directed to a method including transformingor transfecting a cell having larger or increased gaps or distancebetween Okazaki fragments or lowered or reduced frequency of Okazakifragment initiation with one or more or a plurality of nucleic acidsequences. According to certain aspects, a transformed or transfectedcell exhibiting larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragment initiationwhich has one or more or a plurality of nucleic acid sequences insertedinto its genome (for example by a process referred to as recombination),may be further transformed or transfected one or more times resulting ina cell having multiple exogeneous nucleic acid sequences in its genome.

According to one aspect, a method is provided including transforming ortransfecting a cell exhibiting larger or increased gaps or distancebetween Okazaki fragments or lowered or reduced frequency of Okazakifragment initiation using transformation medium or transfection mediumincluding at least one nucleic acid oligomer, replacing thetransformation medium or transfection medium with growth medium,incubating the cell in the growth medium, and repeating the steps oftransforming or transfecting and incubating the cell in growth mediumuntil multiple nucleic acid sequences have been introduced into thecell. In certain aspects, a pool of nucleic acid oligomers is added tothe cell exhibiting larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragment initiationin the transformation or transfection step. In other aspects, anoligomer is single-stranded DNA. In other aspects, multiple mutationsare generated in a chromosome or in a genome. In still other aspects,the growth medium contains an antibiotic, and/or the growth medium isminimal medium. In certain other aspects, a plurality of cellsexhibiting larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragment initiationis contacted with a nucleic acid oligomer in the transformation ortransfection step. In certain other aspects, a plurality of cellsexhibiting larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragment initiationis contacted with a plurality of nucleic acid oligomers in thetransformation or transfection step. In certain other aspects, the cellor cells may be contained within a vessel such as a microfuge tube, atest tube, a cuvette, a multi-well plate, a microfiber, a flow system orother structures or systems known to those of skill in the art forcarrying out the transformation or transfection of cells. According tocertain aspects, the method may be automated.

Embodiments of the present disclosure are directed to attenuatinginteraction between DnaG primase and helicase to increase the amount ofaccessible ssDNA on the lagging strand of the replication fork andenhance multiplex AR frequencies. See FIGS. 1A-1B. Embodiments of thepresent disclosure are directed to cells modified to have impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity, or larger or increased gaps or distancebetween Okazaki fragments or lowered or reduced frequency of Okazakifragment initiation and their use to increase the amount of accessiblessDNA on the lagging strand of the replication fork and enhancemultiplex AR frequencies.

Aspects of the present disclosure are directed to disrupting theinteraction between DnaG primase and DnaB helicase in a cell to increasemultiplex allele replacement frequencies. Aspects of the presentdisclosure are directed to a genetically modified cell, i.e. a cell thathas been genetically modified to impair or inhibit or disrupt primaseactivity or impair or inhibit or disrupt helicase activity or increaseor enlarge gaps or distance between Okazaki fragments or lower or reducefrequency of Okazaki fragment initiation for use with recombinationmethods of introducing one or more exogenous nucleic acids into a cellknown to those of skill in the art and reported in the literature, suchas manual recombination methods, multiplex automated genome engineering(“MAGE”) or co-selection multiplex automated genome engineering(“CoS-MAGE”). It is to be understood that the methods described hereinare useful with any recombination method.

According to the present disclosure, a cell deficient in one or morenucleases is useful in methods of transforming or transfecting cellsdescribed herein. Accordingly, a useful cell may have impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity, or larger or increased gaps or distancebetween Okazaki fragments or lowered or reduced frequency of Okazakifragment initiation, or the cell has increased single stranded DNA(ssDNA) on the lagging strand of the replication fork and the cell maybe deficient in one or more nucleases. Nucleases within the scope of thepresent disclosure include at least those corresponding to the followingnuclease genes: chpA, endA, exoX, mcrB, nfi, recB, recC, recD, recJ,rutC, sbcC, sbcD, tatD, uvrB, vsr, xni, xonA, xseA, xseB, xthA, yhaV,yhbQ, yihG, ploA, polB, and polC. One of skill in the art will readilybe able to identify additional nucleases based on the presentdisclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee. The foregoing and other features and advantages ofthe present invention will be more fully understood from the followingdetailed description of illustrative embodiments taken in conjunctionwith the accompanying drawings in which:

FIGS. 1A-1B are schematics of the effect of dnaG attenuation onreplication fork dynamics.

FIGS. 2A-2C are graphs of data showing that DnaG variants improve MAGEperformance.

FIGS. 3A-3C are graphs of data showing that DnaG variants improveCoS-MAGE performance.

FIGS. 4A-4D are graphs of data showing that placing all targeted alleleswithin one Okazaki fragment does not cause a bimodal distribution forrecombination frequency.

FIGS. 5A-5C are graphs indicating testing of DnaG variants with a20-plex CoS-MAGE oligo set.

FIGS. 6A-6C are graphs showing the effect of dnaG variants andco-selection on leading-targeting CoS-MAGE.

FIG. 7 is a graph showing the effect of dnaG attenuation on deletionfrequency.

DETAILED DESCRIPTION

The present invention provides methods for introducing one or moreexogenous nucleic acid sequences (e.g., engineering genetic mutations)in living cells having impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity, orlarger or increased gaps or distance between Okazaki fragments orlowered or reduced frequency of Okazaki fragment initiation, as well asmethods for constructing combinatorial libraries in vivo, using avariety of microbial, plant and/or animal cells as well as wholeorganisms. In certain embodiments of the invention, one or more or aplurality or a pool of nucleic acids (e.g., single-stranded RNAoligomers, single-stranded DNA oligomers and the like) is introducedinto a set of cells having impaired or inhibited or disrupted primaseactivity or impaired or inhibited or disrupted helicase activity, orlarger or increased gaps or distance between Okazaki fragments orlowered or reduced frequency of Okazaki fragment initiation (e.g., 50microliters) in a suitable transfection and/or transformation medium ina suitable receptacle. According to one aspect, the one or more or aplurality or pool of exogenous nucleic acids contain one or more desiredmutations.

According to one aspect, use of a cell having impaired or inhibited ordisrupted primase activity or impaired or inhibited or disruptedhelicase activity weakens interaction between primase and helicaseresulting in larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragmentinitiation. According to one aspect, use of a cell having impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity minimizes or weakens interaction between theprimase and helicase causing primase to be recruited to the replicationfork in the cell less frequently. This results in fewer Okazakifragments being initiated, longer average Okazaki fragment sizes, andmore exposed ssDNA on the lagging strand. Accordingly, aspects of thepresent disclosure are directed to methods of increasing Okazakifragment length in a cell by using a cell having impaired or inhibitedor disrupted primase activity or impaired or inhibited or disruptedhelicase activity. Accordingly, aspects of the present disclosure aredirected to methods of increasing allele conversion within a cellcomprising using a cell having impaired or inhibited or disruptedprimase activity or impaired or inhibited or disrupted helicase activityin a method of introducing exogenous nucleic acids into the cell.Accordingly, aspects of the present disclosure are directed to methodsof obtaining a cell with a desired set of changes to its genomeincluding transforming or transfecting a cell having impaired orinhibited or disrupted primase activity or impaired or inhibited ordisrupted helicase activity with one or more or a plurality of nucleicacid sequences.

As used herein, the terms “nucleic acid molecule,” “nucleic acidsequence,” “nucleic acid fragment” and “oligomer” are usedinterchangeably and are intended to include, but are not limited to, apolymeric form of nucleotides that may have various lengths, includingeither deoxyribonucleotides or ribonucleotides, or analogs thereof.Oligomers for use in the present invention can be fully designed,partially designed (i.e., partially randomized) or fully randomized. Incertain aspects of the invention, a pool of nucleic acids containssingle-stranded 90-mers of DNA.

Oligomers can be modified at one or more positions to enhance stabilityintroduced during chemical synthesis or subsequent enzymaticmodification or polymerase copying. These modifications include, but arenot limited to, the inclusion of one or more alkylated nucleic acids,locked nucleic acids (LNAs), peptide nucleic acids (PNAs), phosphonates,phosphothioates, and the like in the oligomer. Examples of modifiednucleotides include, but are not limited to 5-fluorouracil,5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine,4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-D46-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,2,6-diaminopurine and the like. Nucleic acid molecules may also bemodified at the base moiety, sugar moiety or phosphate backbone.

The multiple nucleic acid sequences can be targeted for delivery totarget prokaryotic or eukaryotic cells via conventional transformationor transfection techniques. As used herein, the terms “transformation”and “transfection” are intended to refer to a variety of art-recognizedtechniques for introducing an exogenous nucleic acid sequence (e.g.,DNA) into a target cell, including calcium phosphate or calcium chlorideco-precipitation, DEAE-dextran-mediated transfection, lipofection,electroporation, optoporation, injection and the like. Suitabletransfection media include, but are not limited to, water, CaCl_(2,)cationic polymers, lipids, and the like. Suitable materials and methodsfor transforming or transfecting target cells can be found in Sambrook,et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold SpringHarbor Laboratory, Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y., 1989), and other laboratory manuals. In certain aspects ofthe invention, oligomer concentrations of 0.1 to 0.5 micromolar (peroligomer) are used.

Useful receptacles for transfection and/or transformation includereceptacles routinely used by those of skill in the arts oftransfection, transformation and microfluidics. Suitable receptacles foruse in the present invention include, but are not limited to, microfugetubes, test tubes, cuvettes, microscope slides, multi-well plates,microfibers, flow systems, and the like.

Visually detectable markers are suitable for use in the presentinvention, and may be positively and negatively selected and/or screenedusing technologies such as fluorescence activated cell sorting (FACS) ormicrofluidics. Examples of detectable markers include various enzymes,prosthetic groups, fluorescent markers, luminescent markers,bioluminescent markers, and the like. Examples of suitable fluorescentproteins include, but are not limited to, yellow fluorescent protein(YFP), green fluorescence protein (GFP), cyan fluorescence protein(CFP), umbelliferone, fluorescein, fluorescein isothiocyanate,rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride,phycoerythrin and the like. Examples of suitable bioluminescent markersinclude, but are not limited to, luciferase (e.g., bacterial, firefly,click beetle and the like), luciferin, aequorin and the like. Examplesof suitable enzyme systems having visually detectable signals include,but are not limited to, galactosidases, glucorinidases, phosphatases,peroxidases, cholinesterases and the like.

A target cell can be any prokaryotic or eukaryotic cell. For example,target cells can be bacterial cells such as E. coli cells, insect cellssuch as Drosophila melanogaster cells, plant cells such as Arabidopsisthaliana cells, yeast cells, amphibian cells such as Xenopus laeviscells, nematode cells such as Caenorhabditis elegans cells, or mammaliancells (such as Chinese hamster ovary cells (CHO), mouse cells, Africangreen monkey kidney cells (COS), fetal human cells (293T) or other humancells). Other suitable target cells are known to those skilled in theart. Both cultured and explanted cells may be used according to theinvention. The present invention is also adaptable for in vivo use usingviral vectors including, but not limited to, replication defectiveretroviruses, adenoviruses, adeno-associated viruses and the like.

Target cells useful in the present invention include human cellsincluding, but not limited to, embryonic cells, fetal cells, and adultstem cells. Human stem cells may be obtained, for example, from avariety of sources including embryos obtained through in vitrofertilization, from umbilical cord blood, from bone marrow and the like.In one aspect of the invention, target human cells are useful asdonor-compatible cells for transplantation, e.g., via alteration ofsurface antigens of non-compatible third-party donor cells, or throughthe correction of genetic defect in cells obtained from the intendedrecipient patient. In another aspect of the invention, target humancells are useful for the production of therapeutic proteins, peptides,antibodies and the like.

The target cells of the invention can also be used to produce nonhumantransgenic, knockout or other genetically-modified animals. Such animalsinclude those in which a genome, chromosome, gene or nucleic acid isaltered in part, e.g., by base substitutions and/or small or largeinsertions and/or deletions of target nucleic acid sequences. Forexample, in one embodiment, a target cell of the invention is afertilized oocyte or an embryonic stem cell into which the addition ofmultiple nucleic acid sequences has been performed. Such target cellscan then be used to create non-human transgenic animals in whichmultiple nucleic acid sequences have been introduced into their genome.As used herein, a “transgenic animal” is a non-human animal, such as amammal, e.g., a rodent such as a ferret, guinea pig, rat, mouse or thelike, or a lagomorph such as a rabbit, in which one or more of the cellsof the animal includes a transgene. Other examples of transgenic animalsinclude non-human primates, cows, goats, sheep, pigs, dogs, cats,chickens, amphibians, and the like. A transgene is exogenous DNA that isintegrated into the genome of a cell from which a transgenic animaldevelops and which remains in the genome of the mature animal. Aknockout is the removal of endogenous DNA from a cell from which aknockout animal develops, which remains deleted from the genome of themature animal. Methods for generating transgenic and knockout animalsvia embryo manipulation and microinjection, particularly animals such asmice, have become conventional in the art and are described, forexample, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder etal., U.S. Pat. No. 4,873,191 by Wagner et al., and in Hogan, B.,Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press,Cold Spring Harbor, N.Y., 1986).

This invention is further illustrated by the following example, whichshould not be construed as limiting. The contents of all references,patents and published patent applications cited throughout thisapplication are hereby incorporated by reference in their entirety forall purposes.

EXAMPLE I Materials and Methods

Table 1 lists DNA oligonucleotides (“oligo”) used in the Examples. Alloligos were ordered with standard purification and desalting fromIntegrated DNA Technologies. Cultures were grown in LB-Lennox media(LB^(L); 10 g tryptone, 5 g yeast extract, 5 g NaCl per 1 L water).

An asterisk (*) indicates use of a phosphorothioate bond to protectagainst exonuclease activity. See Wang, H. H., Isaacs, F. J., Carr, P.A., Sun, Z. Z., Xu, G., Forest, C. R. and Church, G. M. (2009),Programming cells by multiplex genome engineering and acceleratedevolution, Nature, 460, 894-898.

TABLE 1 Name Used for Sequence ygaR Set 1.850g*c*gaagatcagtaaagatatagaaggtggtatccctggctattaAcaaggtcaggttttgattccattcattaaagatccagtaacaa*a*a (SEQ ID NO: 1) yqaCSet 1.700 a*t*taaaaattatgatgggtccacgcgtgtcggcggtgaggcgtaActtaataaaggttgctctacctatcagcagctctacaatgaat*t*c (SEQ ID NO: 2) gabTSet 1.600 t*c*accattgaagacgctcagatccgtcagggtctggagatcatcagccagtgttttgatgaggcgaagcagtaAcgccgctcctatgc*c*g (SEQ ID NO: 3) ygaUSet 1.500 t*g*acgccaattcccattatccagcaggcgatggctggcaattaaTtactcttccggaatacgcaacacttgccccggataaattttat*c*c (SEQ ID NO: 4) ygaMSet 1.400 g*t*aggtatttttatcggcgcactgttaagcatgcgcaaatcgtaAtgcaaaaatgataataaatacgcgtctttgaccccgaagcctg*t*c (SEQ ID NO: 5) luxSSet 1.300 t*t*tgaactggcttttttcaattaattgtgaagatagtttactgaTtagatgtgcagttcctgcaacttctctttcggcagtgccagtt*c*t (SEQ ID NO: 6) mltBSet 1.250 a*a*ttttacgaggaggattcagaaaaaagctgattagccagagggaagctcacgcccccctcttgtaaatagTtactgtactcgcgcca*g*c (SEQ ID NO: 7) srlESet 1.200 a*c*tgtactgatcgcctggtttgtctccggttttatctatcaataAaggctgaaacatgaccgttatttatcagaccaccatcacccgt*a*t (SEQ ID NO: 8) norWSet 1.150 a*t*cggatgaaagaggcatttggattgttgaaaacattgccgatgtaAgtgggctactgtgcctaaaatgtcggatgcgacgctggcgc*g*t (SEQ ID NO: 9) ascBSet 1.100 a*t*cattctggtggtataaaaaagtgattgccagtaatggggaagatttagagtaAgtaacagtgccggatgcggcgtgaacgccttat*c*c (SEQ ID NO: 10) bioDSet 2.850 t*c*gaagacgcgatctcgctcgcaatttaaccaaatacagaatggTtacaacaaggcaaggtttatgtactttccggttgccgcatttt*c*t (SEQ ID NO: 11) moaESet 2.700 c*g*taaacgtatgtactgagcggtgaaattgccggacgcagcggtgccttatccggctaacaaaaaaTtaccagcgttttgccgcctgc*t*g (SEQ ID NO: 12) ybhMSet 2.600 g*c*gatgtgaagtttagttaagttctttagtatgtgcatttacggTtaatgaaaaaaacgcgtatgcctttgccagacaagcgttatag*c*t (SEQ ID NO: 13) ybhSSet 2.500 t*t*tatcggcctgacgtggctgaaaaccaaacgtcggctggattaAggagaagagcatgtttcatcgcttatggacgttaatccgcaaa*g*a (SEQ ID NO: 14) ybiHSet 2.400 c*a*tatcgacctgattttgcaaggattatcgcaaaggagtttgtaAtgatgaaaaaacctgtcgtgatcggattggcggtagtggtact*t*g (SEQ ID NO: 15) ybiRSet 2.300 t*c*tgaattaatcttcaaaacttaaagcaaaaggcggactcataatccgccttttttatttgccagaccTtagttggccgggagtataa*c*t (SEQ ID NO: 16) yliDSet 2.250 t*t*tcctgtgaggtgattaccctttcaagcaatattcaaacgtaaTtatcctttaattttcggatccagcgcatcgcgtaaaccatcgc*c*c (SEQ ID NO: 17) yliESet 2.200 g*a*ctgactgtaagtacgaacttattgattctggacatacgtaaaTtactcttttactaattttccacttttatcccaggcggagaatg*g*c (SEQ ID NO: 18) ybjKSet 2.150 t*c*ggttcaaggttgatgggttttttgttatctaaaacttatctaTtaccctgcaaccctctcaaccatcctcaaaatctcctcgcgcg*a*t (SEQ ID NO: 19) rimKSet 2.100 c*g*caaaaagcgcaggcaaaaccatgatcagtaatgtgattgcgaTtaaccacccgttttcaggcaatattctgtcgtagcgtggcgtt*c*g (SEQ ID NO: 20) ygfJSet 3.850 c*c*ggacgactttattacagcgaaggaaaggtatactgaaatttaAaaaacgtagttaaacgattgcgttcaaatatttaatccttccg*g*c (SEQ ID NO: 21) recJSet 3.700 g*g*gattgtacccaatccacgctcttttttatagagaagatgacgTtaaattggccagatattgtcgatgataatttgcaggctgcggt*t*g (SEQ ID NO: 22) argOSet 3.600 c*t*ctggaggcaagcttagcgcctctgttttatttttccatcagatagcgcTtaactgaacaaggcttgtgcatgagcaataccgtctc*t*c (SEQ ID NO: 23) yggUSet 3.500 a*a*tccgcaacaaatcccgccagaaatcgcggcgttaattaattaAgtatcctatgcaaaaagttgtcctcgcaaccggcaatgtcggt*a*a (SEQ ID NO: 24) mutYSet 3.400 g*t*ggagcgtttgttacagcagttacgcactggcgcgccggtttaAcgcgtgagtcgataaagaggatgatttatgagcagaacgattt*t*t (SEQ ID NO: 25) glcCSet 3.300 g*c*caccatttgattcgctcggcggtgccgctggagatgaacctgagttaActggtattaaatctgcttttcatacaatcggtaacgct*t*g (SEQ ID NO: 26) yghQSet 3.250 a*c*tgagtcagccgagaagaatttccccgcttattcgcaccttccTtaaatcaggtcatacgcttcgagatacttaacgccaaacacca*g*c (SEQ ID NO: 27) yghTSet 3.200 t*g*gttgatgcagaaaaagcgattacggattttatgaccgcgcgtggttatcactaAtcaaaaatggaaatgcccgatcgccaggaccg*g*g (SEQ ID NO: 28) ygiZSet 3.150 t*t*ctctgtctatgagagccgttaaaacgactctcatagattttaTtaatagcaaaatataaaccgtccccaaaaaagccaccaaccac*a*a (SEQ ID NO: 29) yqiBSet 3.100 a*g*ggttaacaggctttccaaatggtgtccttaggtttcacgacgTtaataaaccggaatcgccatcgctccatgtgctaaacagtatc*g*c (SEQ ID NO: 30) ygfJ_AGRSet 3X.850 c*c*actatgtcagccatcgactgtataattaccgctgccggattatcatcaAGGatggggcaatggaaaatgatgttaccctgggaaca*g*g (SEQ ID NO: 31) ygfT_AGRSet 3X.700 g*a*tgccttcgtatcaaacagagttaacatatcgcgcgccgcctgTCTtcctgcggccattgcagtgacaaccagatccgcgccatgaa*c*t (SEQ ID NO: 32) ubiH_AGRSet 3X.600 g*t*gcagagtttgcgccgcattgcccaccagcacggtacgatgggtaatagaCCTggcggcgtgggttaacgccagcggataagcactg*c*g (SEQ ID NO: 33) argO_AGRSet 3X.500 g*g*attcagccaggtcactgccaacatggtggcgataattttccaCCTgccttgcttcatgacttcggcgctggctaactcaatattac*t*g (SEQ ID NO: 34) yqgC_AGRSet 3X.400 g*a*atcctgagaagcgccgagatgggtataacatcggcaggtatgcaaagcAGGgatgcagagtgcggggaacgaatcttcaccagaac*g*g (SEQ ID NO: 35) trmI_AGRSet 3X.300 t*t*ttttacgcagacgacggctacggttctttgccattatttcacTCTctcgaacattaagtcccatactccgtgaccaagacgatgac*c*a (SEQ ID NO: 36) glcC_AGRSet 3X.250 a*c*gatctgctcgacgttcgcgcattactggagggcgaatcggcaAGActggcggcaacgctgggaacgcaggctgattttgttgtgat*a*a (SEQ ID NO: 37) yghT_AGRSet 3X.200 g*t*gaacatcttattaccgttgtcgaaaaatatggtgctgccgaaAGGgttcatttaggaaaacaggccggaaatgtcggtcgtgcagt*g*a (SEQ ID NO: 38) ygiZ_AGRSet 3X.150 a*a*tacatatacccaaaactcgaacatttcccgcataaagagtttCCTtaagataagaataataagtggcgtaagaagaaaaaatgctg*c*a (SEQ ID NO: 39) cpdA_AGRSet 3X.100 c*t*tcgtgcttttgtgcaaacaggtgagtgtcggtaatttgtaaaatcctgacCCTggcctcaccagccagaggaagggttaacaggct*t*t (SEQ ID NO: 40) lacZ_KO1Set lacZ jackpot +61 T*C*ACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTtGaGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCA*G*C (SEQ ID NO: 41) lacZ_KO2Set lacZ jackpot +264G*C*TGGAGTGCGATCTTCCTGAGGCCGATACTGTCGTCGTCCCCTCAtAaTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAAC*G*T (SEQ ID NO: 42) lacZ_KO3Set lacZ jackpot +420C*A*CATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGtaAATTATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGC*A*A (SEQ ID NO: 43) lacZ_KO4Set lacZ jackpot +602T*G*ATGGTGCTGCGCTGGAGTGACGGCAGTTATCTGGAAGATCAGtAgATGTGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCT*G*C (SEQ ID NO: 44) lacZ_KO5Set lacZ jackpot +693T*A*AACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTaaAATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAGTTCAG*A*T (SEQ ID NO: 45) lacZ_KO6Set lacZ jackpot +1258T*A*CGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACtGaATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTAC*C*G (SEQ ID NO: 46) lacZ_KO7Set lacZ jackpot +1420G*G*GAATGAATCAGGCCACGGCGCTAATCACGACGCGCTGTATtGaTGGATCAAATCTGTCGATCCTTCCCGCCCGGTGCAGTATGAAG*G*C (SEQ ID NO: 47) lacZ_KO8Set lacZ jackpot +1599G*T*CCATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCCGtaGATCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGC*G*G (SEQ ID NO: 48) lacZ_KO9Set lacZ jackpot +1710G*T*TTCGTCAGTATCCCCGTTTACAGGGCGGCTTCGTCTGGGACTaaGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCG*T*G (SEQ ID NO: 49) lacZ_KO10Set lacZ jackpot +1890A*G*CGCTGACGGAAGCAAAACACCAGCAGCAGTTTTTCCAGTTCtGaTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTC*C*G (SEQ ID NO: 50) ygfJ_2*:2*_Set 3.850_lead oligo G*C*CGGAAGGATTAAATATTTGAACGCAATCGTTTAACTACGTTTTTTAAlead ATTTCAGTATACCTTTCCTTCGCTGTAATAAAGTCGTCC*G*G (SEQ ID NO: 51)recJ_2*:2*_ Set 3.700_lead oligoC*A*ACCGCAGCCTGCAAATTATCATCGACAATATCTGGCCAATTTAACGT leadCATCTTCTCTATAAAAAAGAGCGTGGATTGGGTACAATC*C*C (SEQ ID NO: 52) argO_2*:2*_Set 3.600_lead oligo G*A*GAGACGGTATTGCTCATGCACAAGCCTTGTTCAGTTAAGCGCTATCTlead GATGGAAAAATAAAACAGAGGCGCTAAGCTTGCCTCCAG*A*G (SEQ ID NO: 53)yggU_2*:2*_ Set 3.500_lead oligoT*T*ACCGACATTGCCGGTTGCGAGGACAACTTTTTGCATAGGATACTTAA leadTTAATTAACGCCGCGATTTCTGGCGGGATTTGTTGCGGA*T*T (SEQ ID NO: 54) mutY_2*:2*_Set 3.400_lead oligo A*A*AAATCGTTCTGCTCATAAATCATCCTCTTTATCGACTCACGCGTTAAlead ACCGGCGCGCCAGTGCGTAACTGCTGTAACAAACGCTCC*A*C (SEQ ID NO: 55)glcC_2*:2*_ Set 3.300_lead oligoC*A*AGCGTTACCGATTGTATGAAAAGCAGATTTAATACCAGTTAACTCAG leadGTTCATCTCCAGCGGCACCGCCGAGCGAATCAAATGGTG*G*C (SEQ ID NO: 56) yghQ_2*:2*_Set 3.250_lead oligo G*C*TGGTGTTTGGCGTTAAGTATCTCGAAGCGTATGACCTGATTTAAGGAlead AGGTGCGAATAAGCGGGGAAATTCTTCTCGGCTGACTCA*G*T (SEQ ID NO: 57)yghT_2*:2*_ Set 3.200_lead oligoC*C*CGGTCCTGGCGATCGGGCATTTCCATTTTTGATTAGTGATAACCACG leadCGCGGTCATAAAATCCGTAATCGCTTTTTCTGCATCAAC*C*A (SEQ ID NO: 58) ygiZ_2*:2*_Set 3.150_lead oligo T*T*GTGGTTGGTGGCTTTTTTGGGGACGGTTTATATTTTGCTATTAATAAlead AATCTATGAGAGTCGTTTTAACGGCTCTCATAGACAGAG*A*A (SEQ ID NO: 59)yqiB_2*:2*_ Set 3.100_lead oligoG*C*GATACTGTTTAGCACATGGAGCGATGGCGATTCCGGTTTATTAACGT leadCGTGAAACCTAAGGACACCATTTGGAAAGCCTGTTAACC*C*T (SEQ ID NO: 60) exoX.KO*exoX KO oligo t*t*c*g*gcctggagcatgccatgttgcgcattatcgatacagaaacTGAtgcggtttgcagggagggatcgttgagattgcctctgttgatg (SEQ ID NO: 61) xseA.KO*xseA KO oligo g*a*a*t*ttgatctcgctcacatgttaccttctcaatcccctgcaatTGAtttaccgttagtcgcctgaatcaaacggttcgtctgctgcttg (SEQ ID NO: 62) recJ.KO*recJ KO oligo g*g*a*g*gcaattcagcgggcaagtctgccgtttcatcgacttcacgTCAcgacgaagttgtatctgttgtttcacgcgaattatttaccgct (SEQ ID NO: 63) xonA.KO*xonA KO oligo a*a*t*a*acggatttaacctaatgatgaatgacggtaagcaacaatcTGAacctttttgtttcacgattacgaaacctttggcacgcaccccg (SEQ ID NO: 64) Lexo.KO.MM*Lambda exo KO oligo t*g*a*a*acagaaagccgcagagcagaaggtggcagcatgacaccgtaacattatcctgcagcgtaccgggatcgatgtgagagctgtcgaac (SEQ ID NO: 65) dnaG_Q576AOligo to make dnaG gcacgcatggtttaagcaacgaagaacgcctggagctctggacattaaacGQ576A mutation CggaActggcgaaaaagtgatttaacggcttaagtgccg (SEQ ID NO: 66)dnaG_K580A Oligo to make dnaGcgcacgcatggtttaagcaacgaagaacgcctggagctctggacattaaac K580A mutationcaggaActggcgGCaaagtgatttaacggcttaagtgcc (SEQ ID NO: 67) tolC.90.delOligo that deletes gaatttcagcgacgtttgactgccgtttgagcagtcatgtgttaaagcttcendogenous tolC ggccccgtctgaacgtaaggcaacgtaaagatacgggttat(SEQ ID NO: 68) galK_KO1.100 Oligo to delete 100 bpC*G*CGCAGTCAGCGATATCCATTTTCGCGAATCCGGAGTGTAAGAAAACAincluding a portion of CACCGACTACAACGACGGTTTCGTTCTGCCCTGCGCGAT*T*G galK(SEQ ID NO: 69) galK_KO1.149 Oligo to delete 1149 bpC*G*CGCAGTCAGCGATATCCATTTTCGCGAATCCGGAGTGTAAGAAACGAincluding a portion of AACTCCCGCACTGGCACCCGATGGTCAGCCGTACCGACT*G*T galK(SEQ ID NO: 70) galK_KO1.7895 Oligo to delete 7895C*G*CGCAGTCAGCGATATCCATTTTCGCGAATCCGGAGTGTAAGAACTTAbp including a portion CCATCTCGTTTTACAGGCTTAACGTTAAAACCGACATTA*G*Cof galK, galM, gpmA, (SEQ ID NO: 71) aroG, ybgS, zitB, pnuC, and nadAygaR_wt-f Set 1.850_wt-f AAGGTGGTATCCCTGGCTATTAG mascPCR (SEQ ID NO: 72)yqaC_wt-f Set 1.700_wt-f CGGCGGTGAGGCGTAG mascPCR (SEQ ID NO: 73)gabT_wt-f Set 1.600_wt-f TTTTGATGAGGCGAAGCAGTAG mascPCR (SEQ ID NO: 74)ygaY_wt-f Set 1.500_wt-f GTTGCGTATTCCGGAAGAGTAG mascPCR (SEQ ID NO: 75)ygaM_wt-f Set 1.400_wt-f GTTAAGCATGCGCAAATCGTAG mascPCR (SEQ ID NO: 76)luxS_wt-f Set 1.300_wt-f GTTGCAGGAACTGCACATCTAG mascPCR (SEQ ID NO: 77)mltB_wt-f Set 1.250_wt-f GCTGGCGCGAGTACAGTAG mascPCR (SEQ ID NO: 78)srlE_wt-f Set 1.200_wt-f GGTTTGTCTCCGGTTTTATCTATCAATAG mascPCR(SEQ ID NO: 79) norW_wt-f Set 1.150_wt-f GATTGTTGAAAACATTGCCGATGTAGmascPCR (SEQ ID NO: 80) ascB_wt-f Set 1.100_wt-fCCAGTAATGGGGAAGATTTAGAGTAG mascPCR (SEQ ID NO: 81) bioD_wt-fSet 2.850_wt-f AGTACATAAACCTTGCCTTGTTGTAG mascPCR (SEQ ID NO: 82)moaE_wt-f Set 2.700_wt-f GCGGCAAAACGCTGGTAG mascPCR (SEQ ID NO: 83)ybhM_wt-f Set 2.600_wt-f AAGGCATACGCGTTTTTTTCATTAG mascPCR(SEQ ID NO: 84) ybhS_wt-f Set 2.500_wt-f CCAAACGTCGGCTGGATTAG mascPCR(SEQ ID NO: 85) ybiH_wt-f Set 2.400_wt-f AAGGATTATCGCAAAGGAGTTTGTAGmascPCR (SEQ ID NO: 86) ybiR_wt-f Set 2.300_wt-fTTAGTTATACTCCCGGCCAACTAG mascPCR (SEQ ID NO: 87) yliD_wt-fSet 2.250_wt-f CGCTGGATCCGAAAATTAAAGGATAG mascPCR (SEQ ID NO: 88)yliE_wt-f Set 2.200_wt-f TGGGATAAAAGTGGAAAATTAGTAAAAGAGTAG mascPCR(SEQ ID NO: 89) ybjK_wt-f Set 2.150_wt-f TTGAGAGGGTTGCAGGGTAG mascPCR(SEQ ID NO: 90) rimK_wt-f Set 2.100_wt-f GCCTGAAAACGGGTGGTTAG mascPCR(SEQ ID NO: 91) ygfJ_wt-f Set 3.850_wt-f AGCGAAGGAAAGGTATACTGAAATTTAGmascPCR (SEQ ID NO: 92) recJ_wt-f Set 3.700_wt-fTCATCGACAATATCTGGCCAATTTAG mascPCR (SEQ ID NO: 93) argO_wt-fSet 3.600_wt-f TGCACAAGCCTTGTTCAGTTAG mascPCR (SEQ ID NO: 94) yGGU_wt-fSet 3.500_wt-f CAGAAATCGCGGCGTTAATTAATTAG mascPCR (SEQ ID NO: 95)mutY_wt-f Set 3.400_wt-f GGCGCGCCGGTTTAG mascPCR (SEQ ID NO: 96)glcC_wt-f Set 3.300_wt-f GCTGGAGATGAACCTGAGTTAG mascPCR (SEQ ID NO: 97)yghO_wt-f Set 3.250_wt-f CTCGAAGCGTATGACCTGATTTAG mascPCR(SEQ ID NO: 98) yghT_wt-f Set 3.200_wt-f CGCGCGTGGTTATCACTAG mascPCR(SEQ ID NO: 99) ygiZ_wt-f Set 3.150_wt-f TGGGGACGGTTTATATTTTGCTATTAGmascPCR (SEQ ID NO: 100) qyiB_wt-f Set 3.100_wt-fCGATGGCGATTCCGGTTTATTAG mascPCR (SEQ ID NO: 235) ygfJ_wt-fSet 3X.850_wt-f GCTGCCGGATTATCATCAAGA mascPCR (SEQ ID NO: 236) ygfT_wt-fSet 3X.700_wt-f GCAATGGCCGCAGGAAGG mascPCR (SEQ ID NO: 101) ubiH_WTSet 3X.600_wt-f GCACGGTACGATGGGTAATAGAT mascPCR (SEQ ID NO: 102) argO_WTSet 3X.500_wt-f GAAGTCATGAAGCAAGGCAGA mascPCR (SEQ ID NO: 103) yqgC_WTSet 3X.400_wt-f CGGCAGGTATGCAAAGCAGA mascPCR (SEQ ID NO: 104) trmI_WTSet 3X.300_wt-f AGTATGGGACTTAATGTTCGAGAGG mascPCR (SEQ ID NO: 105)glcC_WT Set 3X.250_wt-f AGGGCGAATCGGCAAGG mascPCR (SEQ ID NO: 106)yhgT_WT Set 3X.200_wt-f GAAAAATATGGTGCTGCCGAAAGA mascPCR(SEQ ID NO: 107) ygiZ_WT Set 3X.150_wt-fCTTCTTACGCCACTTATTATTCTTATCTTAAGA mascPCR (SEQ ID NO: 108) cpdA_WTSet 3X.100_wt-f TGGCTGGTGAGGCCAGA mascPCR (SEQ ID NO: 109) exoX.KO*-wt-fexoX wt-f mascPCR GCGCATTATCGATACAGAAACCT primer (SEQ ID NO: 110)xseA.KO*-wt-f exoA wt-f mascPCR CTTCTCAATCCCCTGCAATTTTTACC primer(SEQ ID NO: 111) recJ.KO*-wt-f recJ wt-f mascPCR CAACAGATACAACTTCGTCGCCprimer (SEQ ID NO: 112) xonA.KO*-wt-f xonA wt-f mascPCRGAATGACGGTAAGCAACAATCTACC primer (SEQ ID NO: 113) Lexo_WT-fLambda exo KO wt-f GGCAGCATGACACCGGA mascPCR primer (SEQ ID NO: 114)dnaG_Q576A_ dnaG_Q576A wt-f TGGAGCTCTGGACATTAAACCA wt-f mascPCR primer(SEQ ID NO: 115) dnaG_K580A_ dnaG_K580A wt-f CATTAAACCAGGAACTGGCGAA wt-fmascPCR primer (SEQ ID NO: 116) ygaR_mut-f Set 1.850_mut-fAAGGTGGTATCCCTGGCTATTAA mascPCR (SEQ ID NO: 117) yqaC_mut-fSet 1.700_mut-f CGGCGGTGAGGCGTAA mascPCR (SEQ ID NO: 118) gabT_mut-fSet 1.600_mut-f TTTTGATGAGGCGAAGCAGTAA mascPCR (SEQ ID NO: 119)ygaU_mut-f Set 1.500_mut-f GTTGCGTATTCCGGAAGAGTAA mascPCR(SEQ ID NO: 120) ygaM_mut-f Set 1.400_mut-f GTTAAGCATGCGCAAATCGTAAmascPCR (SEQ ID NO: 121) luxS_mut-f Set 1.300_mut-fGTTGCAGGAACTGCACATCTAA mascPCR (SEQ ID NO: 122) mltB_mut-fSet 1.250_mut-f GCTGGCGCGAGTACAGTAA mascPCR (SEQ ID NO: 123) srlE_mut-fSet 1.200_mut-f GGTTTGTCTCCGGTTTTATCTATCAATAA mascPCR (SEQ ID NO: 124)norW_mut-f Set 1.150_mut-f GATTGTTGAAAACATTGCCGATGTAA mascPCR(SEQ ID NO: 125) ascB_mut-f Set 1.100_mut-f CCAGTAATGGGGAAGATTTAGAGTAAmascPCR (SEQ ID NO: 126) bioD_mut-f Set 2.850_mut-fAGTACATAAACCTTGCCTTGTTGTAA mascPCR (SEQ ID NO: 127) moaE_mut-fSet 2.700_mut-f GCGGCAAAACGCTGGTAA mascPCR (SEQ ID NO: 128) ybhM_mut-fSet 2.600_mut-f AAGGCATACGCGTTTTTTTCATTAA mascPCR (SEQ ID NO: 129)ybhS_mut-f Set 2.500_mut-f CCAAACGTCGGCTGGATTAA mascPCR (SEQ ID NO: 130)ybiH_mut-f Set 2.400_mut-f AAGGATTATCGCAAAGGAGTTTGTAA mascPCR(SEQ ID NO: 131) ybiR_mut-f Set 2.300_mut-f TTAGTTATACTCCCGGCCAACTAAmascPCR (SEQ ID NO: 132) yliD_mut-f Set 2.250_mut-fCGCTGGATCCGAAAATTAAAGGATAA mascPCR (SEQ ID NO: 133) yliE_mut-fSet 2.200_mut-f TGGGATAAAAGTGGAAAATTAGTAAAAGAGTAA mascPCR(SEQ ID NO: 134) ybjK_mut-f Set 2.150_mut-f TTGAGAGGGTTGCAGGGTAA mascPCR(SEQ ID NO: 135) rimK_mut-f Set 2.100_mut-f GCCTGAAAACGGGTGGTTAA mascPCR(SEQ ID NO: 136) tgfJ_mut-f Set 3.850_mut-f AGCGAAGGAAAGGTATACTGAAATTTAAmascPCR (SEQ ID NO: 137) recJ_mut-f Set 3.700_mut-fTCATCGACAATATCTGGCCAATTTAA mascPCR (SEQ ID NO: 138) argO_mut-fSet 3.600_mut-f TGCACAAGCCTTGTTCAGTTAA mascPCR (SEQ ID NO: 139)yggU_mut-f Set 3.500_mut-f CAGAAATCGCGGCGTTAATTAATTAA mascPCR(SEQ ID NO: 140) mutY_mut-f Set 3.400_mut-f GGCGCGCCGGTTTAA mascPCR(SEQ ID NO: 141) glcC_mut-f Set 3.300_mut-f GCTGGAGATGAACCTGAGTTAAmascPCR (SEQ ID NO: 142) yghQ_mut-f Set 3.250_mut-fCTCGAAGCGTATGACCTGATTTAA mascPCR (SEQ ID NO: 143) yghT_mut-fSet 3.200_mut-f CGCGCGTGGTTATCACTAA mascPCR (SEQ ID NO: 144) ygiZ_mut-fSet 3.150_mut-f TGGGGACGGTTTATATTTTGCTATTAA mascPCR (SEQ ID NO: 145)yqiB_mut-f Set 3.100_mut-f CGATGGCGATTCCGGTTTATTAA mascPCR(SEQ ID NO: 146) ygfJ_MUT Set 3X.850_mut-f GCTGCCGGATTATCATCAAGG mascPCR(SEQ ID NO: 147) ygfT_MUT Set 3X.700_mut-f GCAATGGCCGCAGGAAGA mascPCR(SEQ ID NO: 148) ubiH_MUT Set 3X.600_mut-f GCACGGTACGATGGGTAATAGACmascPCR (SEQ ID NO: 149) argO_MUT Set 3X.500_mut-f GAAGTCATGAAGCAAGGCAGGmascPCR (SEQ ID NO: 150) yqgC_MUT Set 3X.400_mut-f GGCAGGTATGCAAAGCAGGmascPCR (SEQ ID NO: 151) trmI_MUT Set 3X.300_mut-fGAGTATGGGACTTAATGTTCGAGAGA mascPCR (SEQ ID NO: 152) glcC_MUTSet 3X.250_mut-f GAGGGCGAATCGGCAAGA mascPCR (SEQ ID NO: 153) yghT_MUTSet 3X.200_mut-f AAAATATGGTGCTGCCGAAAGG mascPCR (SEQ ID NO: 154)ygiZ_MUT Set 3X.150_mut-f CTTCTTACGCCACTTATTATTCTTATCTTAAGG mascPCR(SEQ ID NO: 155) cpdA_MUT Set 3X.100_mut-f GGCTGGTGAGGCCAGG mascPCR(SEQ ID NO: 156) exoX.KO*- exoX mut-f mascPCR GCGCATTATCGATACAGAAACTGAmut-f primer (SEQ ID NO: 157) xseA.KO*- xseA mut-f mascPCRCTTCTCAATCCCCTGCAATTGA mut-f primer (SEQ ID NO: 158) recJ.KO*-recJ mut-f mascPCR CAACAGATACAACTTCGTCGTGA mut-f primer (SEQ ID NO: 159)xonA.KO*- xonA mut-f mascPCR GAATGACGGTAAGCAACAATCTGA mut-f primer(SEQ ID NO: 160) Lexo_MUT-f Lambda exo KO mut-f TGGCAGCATGACACCGTAAmascPRC primer (SEQ ID NO: 161) dnaG_Q576A_ dnaG_Q576A mut-fGGAGCTCTGGACATTAAACGC mut-f mascPCR primer (SEQ ID NO: 162) dnaG_Q580A_dnaG_K580A mut-f ACCAGGAACTGGCGGC mut-f mascPCR primer (SEQ ID NO: 163)ygaR_rev Set 1.850_rev TAGGTAGAGCAACCTTTATTAAGCTACG mascPRC(SEQ ID NO: 164) yqaC_rev Set 1.700_rev TAAAAATATCTACATTTCTGAAAAATGCGCAmascPRC (SEQ ID NO: 165) gabT_rev Set 1.600_rev GCGGCGATGTTGGCTT mascPRC(SEQ ID NO: 166) ygaU_rev Set 1.500_rev AGGGTATCGGGTGGCG mascPRC(SEQ ID NO: 167) ygaM_rev Set 1.400_rev CGCAACGCTTCTGCCG mascPRC(SEQ ID NO: 168) luxS_rev Set 1.300_rev ATGCCCAGGCGATGTACA mascPRC(SEQ ID NO: 169) mltB_rev Set 1.250_rev AGACTCGGCAGTTGTTACGG mascPRC(SEQ ID NO: 170) srlE_rev Set 1.200_rev GGATGGAGTGCACCTTTCAAC mascPRC(SEQ ID NO: 171) norW_rev Set 1.150_rev GTGTTGCATTTGGACACCATTG mascPRC(SEQ ID NO: 172) ascB_rev Set 1.100_rev CGCTTATCGGGCCTTCATG mascPRC(SEQ ID NO: 173) bioD_rev Set 2.850_rev CGGGAAGAACTCTTTCATTTCGC mascPRC(SEQ ID NO: 174) moaE_rev Set 2.700_rev CGTCAATCCGACAAAGACAATCA mascPRC(SEQ ID NO: 175) ybhM_rev Set 2.600_rev TTACTGGCAGGGATTATCTTTACCGmascPRC (SEQ ID NO: 176) ybhS_rev Set 2.500_rev CTGTTGTTAGGTTTCGGTTTTCCTmascPRC (SEQ ID NO: 177) ybiH_rev Set 2.400_rev GTCATAGGCGGCTTGCGmascPRC (SEQ ID NO: 178) ybiR_rev Set 2.300_rev ATGAGCCGGTAAAAGCGACmascPRC (SEQ ID NO: 179) yliD_rev Set 2.250_revAATAAAATTATCAGCCTTATCTTTATCTTTTCGTATAAA mascPRC (SEQ ID NO: 180)yliE_rev Set 2.200_rev CAGCAATATTTGCCACCGCA mascPRC (SEQ ID NO: 181)ybjK_rev Set 2.150_rev AACTTTTCCGCAGGGCATC mascPRC (SEQ ID NO: 182)rimK_rev Set 2.100_rev TACAACCTCTTTCGATAAAAAGACCG mascPRC(SEQ ID NO: 183) ygfJ_rev Set 3.850_rev GATGAACTGTTGCATCGGCG mascPRC(SEQ ID NO: 184) recJ_rev Set 3.700_rev CTGTACGCAGCCAGCC mascPRC(SEQ ID NO: 185) argO_rev Set 3.600_rev AATCGCTGCCTTACGCG mascPRC(SEQ ID NO: 186) yggU_rev Set 3.500_rev TAACCAAAGCCACCAGTGC mascPRC(SEQ ID NO: 187) mutY_rev Set 3.400_rev CGCGAGATATTTTTTCATCATTCCGmascPRC (SEQ ID NO: 188) glcC_rev Set 3.300_rev GGGCAAAATTGCTGTGGCmascPRC (SEQ ID NO: 189) yghQ_rev Set 3.250_rev ACCAACTGGCGATGTTATTCACmascPRC (SEQ ID NO: 190) yghT_rev Set 3.200_rev GACGATGGTGGTGGACGGmascPRC (SEQ ID NO: 191) ygiZ_rev Set 3.150_rev ATCGCCAAATTGCATGGCAmascPRC (SEQ ID NO: 192) yqiB_rev Set 3.100_rev AAAATCCTGACTCTGGCCTCAmascPRC (SEQ ID NO: 193) ygfJ_rev Set 3X.850_rev TCTGTTTGCACTGCGGGTACmascPRC (SEQ ID NO: 194) ygfT_rev Set 3X.700_revTGGTTGGGCAATCTAATAGATTCTCC mascPRC (SEQ ID NO: 195) ubiH_revSet 3X.600_rev atgAGCGTAATCATCGTCGGTG mascPRC (SEQ ID NO: 196) argO_revSet 3X.500_rev CCGTCTCTCGCCAGCTG mascPRC (SEQ ID NO: 197) yqgC_revSet 3X.4050_rev AGCACACGACGTTTCTTTCG mascPRC (SEQ ID NO: 198) trmI_revSet 3X.300_rev ATCTGTTCTTCCGATGTACCTTCC mascPRC (SEQ ID NO: 199)glcC_rev Set 3X.250_rev CTTCCAGCTCGATATCGTGGAG mascPRC (SEQ ID NO: 200)yghT_rev Set 3X.200_rev CACCACCAAAGGTTAACTGTGG mascPRC (SEQ ID NO: 201)ygiZ_rev Set 3X.150_rev CACAAACCAGACAAATACCGAGC mascPRC (SEQ ID NO: 202)cpdA_rev Set 3X.100_rev CGATGGTATCCAGCGTAAAGTTG mascPRC (SEQ ID NO: 203)exoX.KO*-r exoX rev mascPCR GACCATGGCTTCGGTGATG primer (SEQ ID NO: 204)xseA.KO*-r xseA rev mascPCR GGTACGCTTAAGTTGATTTTCCAGC primer(SEQ ID NO: 205) recJ.KO*-r recJ rev mascPCR GGCCTGATCGACCACTTCC primer(SEQ ID NO: 206) xonA.KO*-r xonA rev mascPCR GAAATGTCTCCTGCCAAATCCACprimer (SEQ ID NO: 207) Lexo-r Lambda exo KO rev CAAGGCCGTTGCCGTCmascPCR primer (SEQ ID NO: 208) dnaG_seq-r dnaG rev mascPCRGCTCCATAAGACGGTATCCACA primer for both (SEQ ID NO: 209) Q576A and K580ARx-P19 forward screening GTTTCTCGTGCAATAATTTCTACATC primer for wt tolC(SEQ ID NO: 210) deletion Rx-P20 reverse screeningCGTATGGATTTTGTCCGTTTCA primer for wt tolC (SEQ ID NO: 211) deletionlacZ_jackpot_ forward screening GAATTGTGAGCGGATAACAATTTC seq-fprimer for lacZ (SEQ ID NO: 212) jackpot alleles lacZ_jackpot_reverse screening CCAGCGGCTTACCATCC seq-r primer for lacZ(SEQ ID NO: 213) jackpot alleles cat_mut* cat inactivationG*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTTAATGTACC oligoTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTA*A*A (SEQ ID NO: 214)cat_restore* cat inactivationG*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACC oligoTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTA*A*A (SEQ ID NO: 215)tolC-r_null_ tolC inactivationA*G*CAAGCACGCCTTAGTAACCCGGAATTGCGTAAGTCTGCCGCTAAATC mut* oligoGTGATGCTGCCTTTGAAAAAATTAATGAAGCGCGCAGTCCA (SEQ ID NO: 216) tolC-r_null_tolC inactivation C*A*GCAAGCACGCCTTAGTAACCCGGAATTGCGTAAGTCTGCCGCCGATCrevert* oligo GTGATGCTGCCTTTGAAAAAATTAATGAAGCGCGCAGTCCA (SEQ ID NO: 217)tolC-r_null_ tolC inactivationT*G*GACTGCGCGCTTCATTAATTTTTTCAAAGGCAGCATCACGATCGGCG revert* oligoGCAGACTTACGCAATTCCGGGTTACTAAGGCGTGCTTGCTG (leading targeting)(SEQ ID NO: 218) bla_mut* bla inactivationG*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTATT oligoAGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG (SEQ ID NO: 219)bla_restore* bla reactivationG*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTT oligoCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG (SEQ ID NO: 220)313000.T.lac Cassette primer forTGCTTCTCATGAACGATAACACAACTTGTTCATGAATTAACCATTCCGGAT Z.coMAGE-fT.co-lacZ (lacZ TGAGGCACATTAACGCC coselection) (SEQ ID NO: 221)313001.T.lac Cassette primer forACGGAAACCAGCCAGTTCCTTTCGATGCCTGAATTTGATCCCATAGTTTAT Z.coMAGE-rT.co-lacZ (lacZ CTAGGGCGGCGGATT coselection) (SEQ ID NO: 222)312869.seq-f Screening primer for GAACTTGCACTACCCATCGtolC (lacZ coselection) (SEQ ID NO: 223) 313126.seq-rScreening primer for AGTGACGGGTTAATTATCTGAAAG tolC (lacZ coselection)(SEQ ID NO: 224) 1255700.S.12. Cassette primer forTTTCATCTTGCCAGCATATTGGAGCGTGATCAATTTTGATCAGCTGTGAAC 13b-f S.12.13bAGCCAGGACAGAAATGC (SEQ ID NO: 225) 1255701.S.12. Cassette primer forCATTAGCAGTGATATAACGTAAGTTTTTGTATCACTACACATCAGCCCCCT 13b-r S.12.13bGCAGAAATAAAAAGGCCTGC (SEQ ID NO: 226) 1255550.Seq-f Cassette primer forCATTTTTGCATTACTAATAAGAAAAAGCAAA S.12.13b (SEQ ID NO: 227) 1255850.Seq-rCassette primer for GTCCTAATCATTCTTGTAACATCCTAC S.12.13b(SEQ ID NO: 228) 1710450.Z.16. Cassette primer forTCAGGTTAAAATCATTTAAATTTACACACGCAACAAATATTGACCTACAAG 17b-f Z.16.17bGTGTTGACAATTAATCATCGGC (SEQ ID NO: 229) 1710451.Z.16.Cassette primer for TTTTTACTAGTGAGATAGTCCAGTTTCTGAAAAATAGCCAGTGTAATGTTA17b-r Z.16.17b GCTTGCAAATTAAAGCCTTCG (SEQ ID NO: 230) 1710300.Seq-fScreening primer for TCAGGTAATCCGTTTGCGG Z.16.17b (SEQ ID NO: 231)1710600.Seq-r Screening primer for AACGGCAGATTTTTTCACTGC Z.16.17b(SEQ ID NO: 232) LacZ::KanR. Cassette primer forTGACCATGATTACGGATTCACTGGCCGTCGTTTTACAACGTCGTGCCTGTG full-f lacZ::kanRACGGAAGATCACTTCG (SEQ ID NO: 233) LacZ::KanR. Cassette primer forGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTAACCAG full-r lacZ::kanRCAATAGACATAAGCGG (SEQ ID NO: 234)

EXAMPLE II Strain Creation

Oligo-mediated λ Red recombination was used to generate all mutations asdescribed below. All of the strains described herein were generated fromEcNR2 (Escherichia coli MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857N(cro-ea59)::tetR-bla]). Strain Nuc5−.dnaG.Q576A was generated byrecombining oligo dnaG_Q576A into strain Nuc5− (EcNR2 xonA⁻, recJ⁻,xseA⁻, exoX⁻, and redα⁻; Mosberg, J. A., Gregg, C. J., et al., inreview). EcNR2.DT was created by deleting the endogenous tolC gene usingthe tolC.90.del recombineering oligo. EcNR2.T.co-lacZ was created byrecombining a tolC cassette (T.co-lacZ) into the genome of EcNR2.DT,upstream of the lac operon. CoS-MAGE strains were prepared byinactivating a chromosomal selectable marker (cat, tolC, or bla) using asynthetic oligo. Clones with a sensitivity to the appropriate antibioticor SDS, See Tougu, K. and Marians, K. J. (1996), The Interaction betweenHelicase and Primase Sets the Replication Fork Clock, Journal ofBiological Chemistry, 271, 21398-21405, were identified by replicaplating. The growth rate of strains EcNR2, EcNR2.dnaG.K580A, andEcNR2.dnaG.Q576A are approximately equivalent, while Nuc5−.dnaG.Q576Ahas a doubling time that is only ˜7% longer than the others.

EXAMPLE III Generating dsDNA Cassettes for Recombination

The T.co-lacZ dsDNA recombineering cassette was generated by PCR usingprimers 313000.T.lacZ.coMAGE-f and 313001.T.lacZ.coMAGE-r (Table 1). ThePCR was performed using KAPA HiFi HotStart ReadyMix, with primerconcentrations of 0.5 μM and 1 μμL of T.5.6 used as template (aterminator was introduced downstream of the stop codon in the tolCcassette). PCRs (50 μL total) were heat activated at 95° C. for 5 min,then cycled 30 times at 98° C. (20 sec), 62° C. (15 sec), and 72° C. (45sec). The final extension was at 72° C. for 5 min. The Qiagen PCRpurification kit was used to isolate the PCR products (elution in 30 μLH₂O). Purified PCR products were quantitated on a NanoDrop™ ND1000spectrophotometer and analyzed on a 1% agarose gel with ethidium bromidestaining to confirm that the expected band was present and pure.

EXAMPLE IV Performing λ Red Recombination

λ Red recombinations of ssDNA and dsDNA were performed as previouslydescribed, See DeVito, J. A. (2008), Recombineering with tolC as aselectable/counter-selectable marker: remodeling the rRNA operons ofEscherichia coli, Nucleic Acids Res, 36, e4. Briefly, 30 μL from anovernight culture was inoculated into 3 mL of LB^(L) and grown at 30° C.in a rotator drum until an OD₆₀₀ of 0.4-0.6 was reached (typically 2-2.5hrs). The cultures were transferred to a shaking water bath (300 rpm at42° C.) for 15 minutes to induce λ Red, then immediately cooled on icefor at least 3 minutes. For each recombination, 1 mL of culture waswashed twice in ice cold deionized water (dH₂O). Cells were pelletedbetween each wash by centrifuging at 16,000 rcf for 20 seconds. The cellpellet was resuspended in 50 μL of dH₂O containing the DNA to berecombined. For recombination of dsDNA PCR products, 50 ng of PCRproduct was used. Recombination using dsDNA PCR products was notperformed in Nuc5− strains, since λExo is necessary to process dsDNAinto a recombinogenic ssDNA intermediate prior to β-mediated annealing,See Mosberg, J. A., Lajoie, M. J. and Church, G. M. (2010), Lambda RedRecombineering in Escherichia coli Occurs Through a FullySingle-Stranded Intermediate, Genetics, 186, 791-799. For experiments inwhich a single oligo was recombined, 1 μM of oligo was used. Forexperiments in which sets of ten or twenty recombineering oligos wererecombined along with a co-selection oligo, 0.5 μM of eachrecombineering oligo and 0.2 μM of the co-selection oligo were used (5.2μM total for 10-plex and 10.2 μM total for 20-plex). A BioRadGenePulser™ was used for electroporation (0.1 cm cuvette, 1.78 kV, 200Ω, 25 μF), and electroporated cells were allowed to recover in 3 mLLB^(L) in a rotator drum at 30° C. for at least 3 hours before platingon selective media. For MAGE and CoS-MAGE experiments, cultures wererecovered to apparent saturation (5 or more hours) to minimizepolyclonal colonies (this was especially important for strains based onNuc5−, which exhibit slow recovery after λ Redinduction/electroporation). MAGE recovery cultures were diluted to ˜5000cfu/mL, and 50 μL of this dilution was plated on non-selective LB^(L)agar plates. To compensate for fewer recombinants surviving theco-selection, CoS-MAGE recovery cultures were diluted to ˜1E5 cfu/mL and50 μL of this dilution was plated on appropriate selective media for theco-selected resistance marker (LB^(L) with 50 μg/mL carbenicillin forbla, 20 μg/mL chloramphenicol for cat, or 0.005% w/v SDS for tolC).Leading-targeting CoS-MAGE recovery cultures were diluted to ˜5E6 cfu/mLbefore plating.

EXAMPLE V Recombination Analysis

GalK activity was assayed by plating recovered recombination culturesonto MacConkey agar supplemented with 1% galactose as a carbon source.Red colonies were scored as galK+ and white colonies were galK−. LacZactivity was assayed by plating recovery cultures onto LB^(L) agar+X-gal/IPTG (Fisher ChromoMax IPTG/X-Gal solution). Blue colonies werescored as lacZ+ and white colonies were lacZ−.

PCR analysis was used to confirm genotype. Specifically, Kapa 2G FastReadyMix was used in colony PCRs to screen for correct insertion ofdsDNA selectable markers. PCRs had a total volume of 20 μL, with 0.5 μMof each primer. These PCRs were carried out with an initial activationstep at 95° C. for 2 min, then cycled 30 times at 95° C. (15 sec), 56°C. (15 sec), 72° C. (40 sec), followed by a final extension at 72° C.(90 sec).

Allele-specific colony PCR (ascPCR) was used to detect the dnaG_K580Aand dnaG_Q576A mutations. Multiplex allele-specific colony PCR(mascPCR), See Maresca, M., Erler, A., Fu, J., Friedrich, A., Zhang, Y.M. and Stewart, A. F. (2010), Single-stranded heteroduplex intermediatesin lambda Red homologous recombination, BMC Mol. Biol., 11, was used todetect the 1-2 bp mutations generated in the MAGE and CoS-MAGEexperiments. Each allele is interrogated by two separate PCRs—one with aforward primer whose 3′ end anneals to the wild type allele, and theother with a forward primer whose 3′ end anneals to the mutated allele(the same reverse primer is used in both reactions). Primers aredesigned to have a T_(m) ˜62° C., but a gradient PCR is necessary tooptimize annealing temperature (typically between 63° C. and 67° C.) toachieve maximal specificity and sensitivity for a given set of primers.A wild type allele is indicated by amplification only in thewt-detecting PCR, while a mutant allele is indicated by amplificationonly in the mutant-detecting PCR. For mascPCR assays, primer sets forinterrogating up to 10 alleles are combined in a single reaction. Eachallele has a unique amplicon size (100 bp, 150 bp, 200 bp, 250 bp, 300bp, 400 bp, 500 bp, 600 bp, 700 bp, and 850 bp). Template is prepared bygrowing monoclonal colonies to late-log phase in 150 uL LB^(L) anddiluting 2 uL of culture into 100 uL dH2O. Typical mascPCR reactions useKAPA2GFast Multiplex PCR ReadyMix and 10× Kapa dye in a total volume of10 μL, with 0.2 μM of each primer and 2 μL of template. These PCRs werecarried out with an initial activation step at 95° C. (3 min), thencycled 27 times at 95° C. (15 sec), 63-67° C. (30 sec; annealingtemperature optimized for each set of mascPCR primers), and 72° C. (70sec), followed by a final extension at 72° C. (5 min). All mascPCR andascPCR assays were analyzed on 1.5% agarose/EtBr gels (180 V, durationdepends on distance between electrodes) to ensure adequate bandresolution.

At least two independent replicates for all strains were performed witheach oligo set in CoS-MAGE experiments. All replicates for a givenstrain and oligo set were combined to generate a complete data set.Polyclonal or ambiguous mascPCR results were discarded. Mean number ofalleles replaced per clone were determined by scoring each allele as 1for converted or 0 for unmodified. Data for EcNR2 and Nuc5− are fromMosberg, J A, Gregg, C J, et al. (in review). Given the sample sizestested in the CoS-MAGE experiments (n>47), parametric statisticalanalyses were used instead of their non-parametric equivalents, sincethe former are more robust with large sample sizes, See Wang, H. H. andChurch, G. M. (2011), Multiplexed genome engineering and genotypingmethods applications for synthetic biology and metabolic engineering,Methods Enzymol, 498, 409-426. A one way ANOVA was used to test forsignificant variance in CoS-MAGE performance of the strains (EcNR2,EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, & EcNR2.nuc5−.dnaG.Q576A) for agiven oligo set. Subsequently, a Student's t-test was used to makepairwise comparisons with significance defined as p<0.05/n, where n isthe number of pairwise comparisons. Here, n=15 as this data set wasplanned and collected as part of a larger set with 6 different strainsalthough only EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, &EcNR2.nuc5−.dnaG.Q576A are presented here. As such, significance wasdefined as p<0.003 for the analyses presented in FIGS. 3A-3C and 5A-5C.Statistical significance in FIGS. 3A-3C and 5A-5C are denoted using astar system where * denotes p<0.003, ** denotes p<0.001, and *** denotesp<0.0001. In the case of the experiment comparing EcNR2 andEcNR2.dnaG.Q576A using leading targeting oligos (FIGS. 6A-6C),statistical significance was tested using a single t-test withsignificance defined as p<0.05.

For the experiment in which 10 oligos were targeted within lacZ,recombinants were identified by blue/white screening. The frequency ofclones with 1 or more alleles replaced (# of white colonies/total # ofcolonies) was determined for every replicate. For white colonies only, aportion of lacZ gene was amplified with primers lacZ_jackpot_seq-f andlacZ_jackpot_seq-r (Table 1), using KAPA HiFi HotStart ReadyMix asdescribed above. PCR purified (Qiagen PCR purification kit) ampliconswere submitted to Genewiz for Sanger sequencing in both directions usingeither lacZ_jackpot_seq-f or lacZ_jackpot_seq-r. Combined, the twosequencing reads for each clone interrogated all 10 alleles (i.e.,unmodified or mutant sequence). Three replicates of recombinations andblue/white analysis were performed to ensure consistency, but only onereplicate was sequenced (n=39 for EcNR2 and n=55 for EcNR2.dnaG.Q576A).Mean number of alleles replaced per clone were determined as describedabove. We tested for statistically significant differences in meanallele conversion between the strains using a Student's t-test withsignificance defined as p<0.05. Statistical significance in FIG. 4C isdenoted using a star system where *** denotes p<0.0001.

EXAMPLE VI Impaired Primase Activity Enhances Multiplex AlleleReplacement Frequency

It is generally accepted that Redβ mediates annealing of exogenous DNAto the lagging strand of the replication fork prior to extension as anascent Okazaki Fragment, See Jekel, J. F., Katz, D. L., Elmore, J. G.and Wild, D. (2001), Epidemiology, Biostatistics, & PreventativeMedicine. W. B. Saunders. The amount of ssDNA on the lagging strand wasincreased by disrupting the ability of DnaG primase to initiate OFs.DnaG K580A and Q576A mutations increase OF length in vitro byapproximately 1.5-fold and 8-fold, respectively. See Table 2 which is anestimation of Okazaki fragment length in EcNR2.dnaG.K580A andEcNR2.dnaG.Q576A.

TABLE 2 WT dnaG K580A Q576A [Primase] Okazaki Okazaki Okazaki (nM) Frag(kb) Frag (kb) Frag (kb) 80 2.5 5 23 160 1.5 2.5 18 320 1 1 8 640 0.8 nd3 Average Fold effect compared to WT 1.6 8.2

According to Table 2, average Okazaki Fragment length was estimatedbased on in vitro results (gel images) from Tougu, K. and Marians, K. J.(1996), The Interaction between Helicase and Primase Sets theReplication Fork Clock, Journal of Biological Chemistry, 271,21398-21405 for the same DnaG primase variants, tabulated above. Thefold difference in OF sizes for the specified primase concentrationswere compared and the average fold difference was determined (variant OFlength/wt OF length). The in vivo OF lengths of ˜2.3-3.1 kb and ˜12-16kb were estimated for the K580A and Q576A mutants, respectively, basedon the reported ˜1.5-2 kb OF lengths in wt cells grown in rich media.See Corn, J. E. and Berger, J. M. (2006), Regulation of bacterialpriming and daughter strand synthesis through helicase-primaseinteractions, Nucleic Acids Res., 34, 4082-4088; Lia, G., Michel, B. andAllemand, J. F. (2012), Polymerase Exchange During Okazaki FragmentSynthesis Observed in Living Cells, Science, 335, 328-331; Okazaki, R.,Okazaki, T., Sakabe, K., Sugimoto, K. and Sugino, A. (1968), Mechanismof DNA chain growth. I. Possible discontinuity and unusual secondarystructure of newly synthesized chains, Proceedings of the NationalAcademy of Sciences, 59, 598-605. However, these approximations may beimperfect since Tougu et al. performed this analysis in vitro and didnot use the same EcNR2.dnaG.K580A and EcNR2.dnaG.Q576A strains. Otherconditions and/or host factors not accounted for in vitro may affectpriming efficiency.

EcNR2, EcNR2.dnaG.K580A, and EcNR2.dnaG.Q576A were compared to determinewhether longer OFs would improve recombination of exogenous nucleicacids. Three sets of recombineering oligos (designed in to convert TAGcodons to TAA and renamed herein for clarity as Sets 1-3) were used inorder to control for potential oligo-, allele-, region-, andreplichore-specific effects. FIG. 1A is a schematic showing thereplication fork in E. coli, including the leading and lagging strandsundergoing DNA synthesis. DnaG synthesizes RNA primers (red) onto thelagging template strand, which in turn initiate Okazaki fragmentsynthesis (blue) by PolIII. Compared to wt DnaG primase, the variantstested have lower affinities for DnaB helicase. Since the DnaG-DnaBinteraction is necessary for primase function, primer synthesis occursless frequently, thereby exposing larger regions of ssDNA on the laggingtemplate strand. FIG. 1B is a schematic representing the E. coli MG1655genome with the origin (oriC) and terminus (T) of replication indicated,splitting the genome into Replichore 1 and Replichore 2. Each oligo setconverts 10 TAG codons to TAA codons within the genomic regionsindicated in gray. Co-selection marker positions are denoted by radiallines. The genomic regions targeted by these oligo sets are indicated inFIG. 1B. The AR distribution shifted to the right for EcNR2.dnaG.Q576A,as reflected by the increase in mean number of alleles converted perclone per MAGE cycle. See FIGS. 2A-2C. EcNR2 (wt) and EcNR2.dnaG.Q576A(Q576A) were tested for their MAGE performance without co-selectionusing three sets of 10 oligos as described in FIG. 1B. For each set, all10 alleles were simultaneously assayed by mascPCR after one cycle ofMAGE. The data are presented using stacked AR frequency plots, whichshow the distribution of clones exhibiting a given number of alleleconversions. Compared to EcNR2 (A, Set 1, n=69; B, Set 2, n=47; C, Set3, n=96), EcNR2.dnaG.Q576A exhibited fewer clones with zero conversionsfor Set 1 (A, n=90) and Set 3 (C, n=96), but not for Set 2 (B, n=46). Inall three sets, EcNR2.dnaG.Q576A displayed more clones with 2 or moreallele conversions.

CoS-MAGE was then used in a similar experiment. In this experiment, eachof the three oligo sets was paired with a co-selection oligo whichrestored the function of a nearby mutated selectable marker (cat for Set1, bla for Set 2, and tolC for Set 3). Also, the dnaG.Q576A mutation wasintroduced into Nuc5−. EcNR2.dnaG.Q576A robustly outperformed EcNR2,yielding a significantly increased mean number of alleles converted(mean±std. error of mean) for Set 1 (FIG. 3B, left panel, 1.43±0.12 vs.0.96±0.07, **p=0.0003), Set 2 (FIG. 3B, middle panel, 2.63±0.13 vs.2.04±0.10, **p=0.0003), and Set 3 (FIG. 3B, right panel, 2.54±0.14 vs.1.22±0.07, ***p<0.0001). In agreement with the previous observation forMAGE without co-selection, EcNR2.dnaG.Q576A exhibited an increased ARdistribution for all three oligo sets in CoS-MAGE (FIG. 3A).Furthermore, EcNR2.dnaG.K580A (intermediate-sized OFs) appears to haveintermediate performance between EcNR2 (normal OFs) and EcNR2.dnaG.Q576A(longest OFs) indicating that OF length correlates with AR frequency anddemonstrating that exposing more ssDNA at the lagging strand of thereplication fork enhances Redβ-mediated annealing.

Visualizing AR frequency for individual alleles in all three Sets (FIG.3C) reinforces the relationship between OF size and MAGE performance.Compared to EcNR2, the K580A variant trends toward a modest increase inindividual AR frequency, whereas the Q576A variant starkly improves ARfrequency. Finally, the Nuc5−.dnaG.Q576A strain yielded the highestobserved AR frequencies for all oligo sets, suggesting a combined effectof decreasing oligo degradation through nuclease inactivation andincreasing the amount of exposed target ssDNA at the lagging strand ofthe replication fork. EcNR2.dnaG.Q576A strongly outperformed Nuc5− forSet 3 (***p<0.0001), whereas EcNR2.dnaG.Q576A performance was notsignificantly different than that of Nuc5− for Sets 1 (p=0.33) and 2(p=0.26). See Tables 3 and 4. This suggests that the relative importanceof replication fork availability and oligo protection can vary for MAGEtargets throughout the genome, possibly due to oligo and/orlocus-specific effects that have not yet been elucidated.

TABLE 3 EcNR2 Nuc5- Nuc5- Mean ± Mean ± EcNR2.dnaG.Q576A .dnaG.Q576A SEMSEM Mean ± SEM Mean ± SEM Set (n) (n) (n) (n) 1 0.96 ± 0.07 1.58 ± 0.101.43 ± 0.12 2.30 ± 0.25 (319) (257) (141) (92) 2 2.04 ± 0.10 2.89 ± 0.192.63 ± 0.13 3.72 ± 0.17 (269) (142) (236) (191) 3 1.22 ± 0.07 1.61 ±0.12 2.54 ± 0.14 2.59 ± 0.19 (327) (139) (184) (92)

Table 3 is a summary of mean number of alleles converted per clone foreach MAGE oligo set. The mean number of alleles converted per clone,standard error of the mean (SEM), and sample size (n) were compared forEcNR2, Nuc5−, EcNR2.dnaG.Q576A, and Nuc5−.dnaG.Q576A. Nuc5− andEcNR2.dnaG.Q576A had statistically equivalent performance for Sets 1 and2, while EcNR2.dnaG.Q576A strongly outperformed Nuc5− for Set 3.Nuc5−.dnaG.Q576A consistently outperformed all other strains. Data forEcNR2.dnaG.Q576A and Nuc5−.dnaG.Q576A were determined in this work. Datafor EcNR2 and Nuc5− are from Mosberg, J. A., Gregg, C. J., et al. (inreview).

TABLE 4 CoS-MAGE Allele Replacement performance of modified strains(presented as fold change from EcNR2) Metric Set Nuc5- E2.dnaG.Q.576ANuc5-.dnaG.Q.576A Average 1 1.65 1.49 2.40 2 1.41 1.29 1.82 3 1.32 2.082.12 Average 1.46 1.62 2.11 5+ 1 5.28 3.96 10.18 Conversions 2 2.65 2.014.11 3 1.07 4.20 4.52 Average 3.00 3.39 6.27 0 1 0.67 0.68 0.24Conversions 2 0.58 0.79 0.35 3 0.71 0.40 0.30 Average 0.65 0.62 0.29

Table 4 shows CoS-MAGE allele replacement performance of modifiedstrains (presented as fold change from EcNR2). The fold improvement wascalculated as (strain performance)/(EcNR2 performance), whereperformance refers to the average number of allele conversions perclone, or the fraction of clones with 5+ or 0 conversions. These metricswere the average of individual metrics for Oligo Sets 1, 2, and 3. Inall three categories, Nuc5−.dnaG.Q576A exhibited an effect that wasroughly an additive combination of the effects yielded in Nuc5− andEcNR2.dnaG.Q576A. Data for EcNR2.dnaG.Q576A and Nuc5−.dnaG.Q576A weredetermined in this work. Data for EcNR2 and Nuc5− are from Mosberg, J.A., Gregg, C. J., et al. (in review).

With respect to FIGS. 3A-3C, EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A,and Nuc5−.dnaG.Q576A were tested for their performance in CoS-MAGE usingthree sets of 10 oligos as described in FIG. 1B. For each set, all 10alleles were simultaneously assayed by mascPCR in recombinant clonesafter one cycle of CoS-MAGE. (A) The data are presented using stacked ARfrequency plots, which show the distribution of clones exhibiting agiven number of allele conversions. (B) Mean number of alleles convertedfor each strain are shown with p-values indicated above the bars.Statistical significance is denoted using a star system where * denotesp<0.003, ** denotes p<0.001, and *** denotes p<0.0001. The data arepresented as the mean (reported numerically inside each bar)±standarderror of the mean. (C) AR frequencies for each individual allele areshown for all tested strains. Overall, the relative performance of eachstrain was Nuc5−.dnaG.Q576A>EcNR2.dnaG.Q576A>EcNR2.dnaG.K580A>EcNR2.This trend reflects an improvement commensurate with the severity ofprimase attenuation (i.e. the Q576A variant has more severely disruptedprimase and larger OFs than the K580A variant). Furthermore,Nuc5−.dnaG.Q576A combines the benefits of the DnaG Q576A variant and thebenefits of the inactivation of 5 potent exonucleases (Mosberg, J. A.,Gregg, C. J., et al., in review). For Set 1: EcNR2, n=319;EcNR2.dnaG.K580A, n=93; EcNR2.dnaG.Q576A, n=141; Nuc5³¹ .dnaG.Q576A,n=47. For Set 2: EcNR2, n=269; EcNR2.dnaG.K580A, n=111;EcNR2.dnaG.Q576A, n=236; Nuc5⁻.dnaG.Q576A, n=191. For set 3: EcNR2,n=327; EcNR2.dnaG.K580A, n=136; EcNR2.dnaG.Q576A, n=184;Nuc5⁻.dnaG.Q576A, n=92.

EXAMPLE VII Okazaki Fragment Location Is Not a Major Determinant ofAvailable ssDNA on the Lagging Strand of the Replication Fork

Given the significant enhancement of CoS-MAGE performance inEcNR2.dnaG.Q576A, it was investigated whether localizing all 10 targetedalleles to a single putative OF would result in “jackpot” recombinantswith all 10 alleles converted. Without wishing to be bound by scientifictheory, nascent Okazaki Fragments sometimes obstruct target alleles,leading to a non-accessible lagging strand. Successful replacement ofone allele should indicate permissive OF localization, greatlyincreasing the chance that other alleles occurring within the same OFcould be replaced. The larger OF size in EcNR2.dnaG.Q576A may allow manychanges to occur within 1 large OF. Therefore, 10 MAGE oligos weredesigned that introduce inactivating nonsense mutations into a regionspanning 1829 bp of lacZ. Despite their close proximity, all 10 alleleswere spaced far enough apart that their corresponding MAGE oligos wouldnot overlap. Given the difference in average OF sizes between strains,it is unlikely for all 10 alleles to be located in the same OF in EcNR2,but quite likely that all 10 alleles would be located in the same OF inEcNR2.dnaG.Q576A. A tolC cassette (T.co-lacZ) was installed ˜50 kbupstream of lacZ for efficient co-selection. Prior to use, this cassettewas inactivated using the tolC-r_null_mut* oligo. Since the placement ofthese mutations is not compatible with mascPCR analysis, Sangersequencing was used for analysis of white colonies. Blue colonies werescored as having zero conferred mutations. For EcNR2, 59% of the cloneswere white with 1.24±0.23 (mean ±standard error of the mean) conversionsper clone, whereas 84% of the EcNR2.dnaG.Q576A clones were white with2.52±0.25 allele conversions per clone (FIG. 4A, 4C). WhileEcNR2.dnaG.Q576A exhibits more mean allele conversions in CoS-MAGE thanEcNR2 (***p<0.0001), the magnitude of this improvement (FIG. 4B) iscomparable with those observed for Sets 1-3 (FIGS. 3A-3C) wherenon-selectable oligos were spread across 70, 85, and 162 kb,respectively. Moreover, “jackpot” clones with 7+ converted alleles werenot frequently observed for EcNR2.dnaG.Q576A using this oligo set. Thusalthough replication fork position is relevant, OF placement is not thepredominant limiting factor for multiplex allele replacement. Otherimportant factors could include target site occlusion by single strandedbinding proteins or the availability of oligos, Redβ, or host factors.

With respect to FIGS. 4A-4D, EcNR2 and EcNR2.dnaG.Q576A were tested fortheir performance in CoS-MAGE using a set of 10 non-overlapping oligosthat introduce 10 premature stop codons in the first 1,890 bp of lacZ.The targeted region of the genome is likely to be small enough to befrequently encompassed within a single Okazaki Fragment inEcNR2.dnaG.Q576A. After one cycle of CoS-MAGE, LacZ⁻ recombinant cloneswere Sanger sequenced to assay all 10 alleles. Recombinations wereperformed in triplicate to estimate the frequency of white colonies(lacZ⁻), but sequencing was only performed on a single replicate. (A)EcNR2.dnaG.Q576A (n=715, 5.33:1) exhibited a significant increase in thelacZ⁻:lacZ⁺ ratio compared to EcNR2 (n=485, 1.46:1). (B)EcNR2.dnaG.Q576A exhibited an AR distribution similar to those observedwith Sets 1-3 (which span 70 kb, 85 kb, and 162 kb, respectively). (C)Compared to EcNR2, EcNR2.dnaG.Q576A exhibited a higher mean number ofalleles converted (unpaired t-test, ***p<0.0001). For EcNR2, n=39, andfor EcNR2.dnaG.Q576A, n=55. (D) Compared to EcNR2, AR frequenciesincreased for 9 out of 10 individual alleles in EcNR2.dnaG.Q576A. Thealleles are represented by their positions in lacZ (e.g., “+61” meansthat this oligo introduces a nonsense mutation by generating a mismatchat the 61^(st) nucleotide of lacZ). Taken together, all of these resultsdemonstrate improved CoS-MAGE in EcNR2.dnaG.Q576A compared to EcNR2, butno significant enhancement was obtained from targeting all oligos to asingle putative OF.

EXAMPLE VIII Improved Strains Have Larger Optimal Oligo Pool Size forMultiplex Allele Replacement

A MAGE oligo pool size of approximately 10 was found to be mosteffective in prior studies. 10 additional MAGE oligos (Set 3X) weredesigned that swapped synonymous AGA and AGG codons in alleles withinthe same region targeted by the Set 3 oligos. The ygfT allele (Set 3X)was not successfully assayed by mascPCR, so a maximum of 19 allelereplacements could be detected out of the 20 conversions attempted. Oneround of CoS-MAGE using the combined oligo Sets 3 and 3X with tolC as aselectable marker improved AR frequency in all strains (FIG. 5A). Themean number of alleles converted (and fold increase over 10-plex meansfor Set 3 alone) per clone are as follows: 1.65 (1.35-fold) for EcNR2;1.97 (1.02-fold) for EcNR2.dnaG.K580A; 2.96 (1.17-fold) forEcNR2.dnaG.Q576A; and 4.50 (1.74-fold) for Nuc5−.dnaG.Q576A (FIG. 5B).Nuc5−.dnaG.Q576A exhibited the greatest improvement with the expandedoligo set, suggesting that preventing oligo degradation is importantwhen the intracellular concentration of each individual oligo is low.Longer OFs then increase the probability that scarce oligos will findtheir genomic target. This observation assumes that a limited number ofoligos are internalized during electroporation, which is consistent withthe fact that the mole fraction of an oligo in a multiplex experimentaffects its relative AR frequency at saturating oligo concentrations.Notably, the Set 3X oligos yielded lower recombination frequenciescompared to the Set 3 alleles that converted TAG to TAA codons, andNuc5−.dnaG.Q576A strongly elevated the AR frequency of these alleles(FIG. 5C). Nuc5−.dnaG.Q576A exhibited the largest number of simultaneousallele conversions in a single recombination (tolC plus 12 additionalalleles converted).

With respect to FIGS. 5A-5C, EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A,and Nuc5−.dnaG.Q576A were tested for their performance in CoS-MAGE usingan expanded set of 20 oligos (Sets 3+3X). Genotypes of recombinantclones were assayed by mascPCR after one cycle of CoS-MAGE (ygfT couldnot be assayed by mascPCR). (A) AR frequency distributions. (B) Meannumber of alleles converted ±standard error of the mean, with p-valuesindicated above the bars. Statistical significance is denoted using astar system where * denotes p<0.003, ** denotes p <0.001, and ***denotes p<0.0001. (C) Mean individual AR frequencies. As seen with thesmaller oligo sets, the dnaG variants reduce the number of clones withzero conversions and increase the average number of conversions perclone. Nuc5⁻.dnaG.Q576A strongly outperforms all other strains, with amean of 4.50 alleles converted and fewer than 10% of clones having zeroconversions. Notably, Nuc5−.dnaG.Q576A has strongly improved performancewith Sets 3+3X compared to Set 3, whereas EcNR2.dnaG.Q576A does not.EcNR2, n=96; EcNR2.dnaG.K580A, n=113; EcNR2.dnaG.Q576A, n=95;Nuc5⁻.dnaG.Q576A, n=96.

EXAMPLE IX Disrupting DnaG Primase Activity Enhances Leading StrandRecombination

Since DnaG primase synthesizes RNA primers only at the lagging strand ofthe replication fork, its alteration has minimal effect on Redβ-mediatedannealing to the leading strand. Oligos designed to target the Set 3alleles on the leading strand (reverse complements of the Set 3 oligosdescribed above) were tested. The tolC-reverting co-selection oligo wasalso re-designed to target the leading strand so that the correct strandwould be co-selected. Although the number of tolC-reverted co-selectedrecombinants were few, of the tolC+ clones, EcNR2 gave 0.85±0.13 alleleconversions per clone (mean±std. error of the mean, n=88), whereasEcNR2.dnaG.Q576A gave 1.39±0.18 conversions (n=91), which wassignificantly different (*p=0.018). Similar to lagging targeting Set 3,a reduction in zero conversion events for EcNR2.dnaG.Q576A was observed,as well as a broadening of the distribution of total allele conversionsper clone and a greater maximum number of alleles converted (FIG. 6A).Leading-targeting CoS-MAGE yields recombination frequencies nearlywithin two-fold of those attained with lagging-targeting CoS-MAGE(1.22±0.07 vs. 2.54±0.14 for EcNR2 and EcNR2.dnaG.Q576A, respectively).EcNR2.dnaG.Q576A exhibited significantly enhanced AR frequency overEcNR2 at 9 out of 10 alleles on the leading strand (FIG. 6C). Usingleading targeting oligos, the co-selection advantage diminished withdistance (FIG. 6B, top panel). In contrast, co-selection using laggingtargeting oligos increases the AR frequency of other alleles spanning alarge genomic distance (−0.5 Mb; (9)), as observed for thelagging-targeting Set 3 oligos (FIG. 6B, bottom panel).

More specifically, FIG. 6A-6C are described as follows. (A)EcNR2.dnaG.Q576A (n=91) outperformed EcNR2 (wt, n=88) inleading-targeting Set 3 CoS-MAGE, with a reduction in zero conversionevents as well as a broadening of the distribution of total alleleconversions per clone. (B) For leading-targeting Set 3 oligos, ARfrequency decays rapidly with increasing distance from the selectablemarker (top panel). In contrast, co-selection using the correspondingset of lagging targeting oligos (see also FIG. 3C, right panel) providesrobust co-selection spanning at least 0.162 Mb (bottom panel). For thelagging-targeting oligos (bottom panel), linear regression analyses(solid trendline) show that co-selection does not decrease with distancefor either strain over this 0.162 Mb genomic region. (C) IndividualCoS-MAGE AR frequency is plotted for each leading-targeting Set 3 oligoin EcNR2 (wt) and EcNR2.dnaG.Q576A (Q576A). AR frequency is improved for9/10 alleles in EcNR2.dnaG.Q576A. Note that the most proximal allele tothe selectable marker (yqiB) is separated from the other alleles with abroken axis, since its AR frequency was much higher than that of theothers.

EXAMPLE X Disrupting DnaG Primase Activity Enhances Deletions But NotInsertions

MAGE is most effective at introducing short mismatches, insertions, anddeletions, as these can be efficiently generated using λ Red-mediatedrecombination without direct selection. However, large deletions andgene-sized insertions are also important classes of mutations that couldincrease the scope of applications for MAGE. For example, combinatorialdeletions could be harnessed for minimizing genomes, See Erler, A.,Wegmann, S., Elie-Caille, C., Bradshaw, C. R., Maresca, M., Seidel, R.,Habermann, B., Muller, D. J. and Stewart, A. F. (2009), ConformationalAdaptability of Red beta during DNA Annealing and Implications for ItsStructural Relationship with Rad52, J. Mol. Biol., 391, 586-598, andefficient insertions could increase the ease of building biosyntheticpathways by removing the need for linking inserted genes to selectablemarkers, See Posfai, G., Plunkett, G., Feher, T., Frisch, D., Keil, G.M., Umenhoffer, K., Kolisnychenko, V., Stahl, B., Sharma, S. S., deArruda, M. et al. (2006), Emergent properties of reduced-genomeEscherichia coli, Science, 312, 1044-1046 and Blomfield, I. C., Vaughn,V., Rest, R. F. and Eisenstein, B. I. (1991), Allelic exchange inEscherichia coli using the Bacillus subtilis sacB gene and atemperature-sensitive pSC101 replicon, Mol. Microbiol., 5, 1447-1457 andWarming, S., Costantino, N., Court, D. L., Jenkins, N. A. and Copeland,N. G. (2005) Simple and highly efficient BAC recombineering using galKselection, Nucleic Acids Res., 33, e36. Large deletions require twoseparate annealing events often spanning multiple OFs, but largeinsertions should anneal within the same OF, as the heterologous portionloops out and allows the flanking homologies to anneal to their adjacenttargets. Maresca et al. have demonstrated that the length of deletionshave little effect on Redβ-mediated recombination, but that insertionfrequency is highly dependent on insert size (presumably due toconstraints on λExo-mediated degradation of the leading-targeting strandand not the lagging-targeting strand). The following study was conductedto determine whether diminishing DnaG primase function would enhancedeletion and/or insertion frequencies.

Three oligos were designed that deleted 100 bp, 1,149 bp, or 7,895 bp ofthe genome, including a portion of galK. In addition to galK, oligogalK_KO1.7895 deleted several nonessential genes (galM, gpmA, aroG,ybgS, zitB, pnuC, and nadA). The recombined populations were screenedfor the GalK− phenotype (white colonies) on MacConkey agar platessupplemented with galactose as a carbon source. EcNR2.dnaG.Q576Asignificantly outperformed EcNR2 for the 100 bp (*p=0.03) and 1,149 bp(*p=0.03) deletions, but there was no difference detected between thetwo strains for the 7,895 bp deletion (p=0.74, FIG. 7). The lack ofimprovement using galK_KO1.7895 may be due to reduced targetavailability if the two homology sites are split across two or more OFseven in EcNR2.dnaG.Q576A. From the perspective of the ssDNA intermediatemodel for λRed recombination, deletion frequency was enhanced inEcNR2.dnaG.Q576A especially for intermediate-sized deletions (500 bp-10kb), since less frequent priming increases the probability of bothhomology regions being located in the same OF.

FIG. 7 is described as follows. DnaG primase disruption enhancesgene-sized deletion frequency. Oligos that deleted 100 bp, 1,149 bp, or7,895 bp of the genome, including a portion of galK, were recombinedinto EcNR2 and EcNR2.dnaG.Q576A. The recombined populations werescreened for the GalK− phenotype (white colonies) on MacConkey agarplates supplemented with galactose as a carbon source. EcNR2.dnaG.Q576Asignificantly outperformed EcNR2 for the 100 bp and 1,149 bp deletions,but there was no difference detected between the two strains for the7,895 bp deletion.

The insertion frequency of a selectable kanamycin resistance cassette(lacZ::kanR, 1.3 kb) targeted to lacZ was quantified. Insertion oflacZ::kanR (4, 14) in three replicates yielded recombination frequenciesof 1.81E-04 ±6.24E-05 in EcNR2 versus 1.28E-04 ±4.52E-05 inEcNR2.dnaG.Q576A (p=0.30 by unpaired t-test). Modifying DnaG primasefunction does not appear to significantly affect λ Red-mediated geneinsertion.

REFERENCES

References identified herein and listed as follows are herebyincorporated by reference herein in their entireties for all purposes.The references identified below may be referred to herein by the numberassociated with the reference.

-   1. Smith, H. O., Hutchison, C. A., Pfannkoch, C. and Venter,    J.C. (2003) Generating a synthetic genome by whole genome assembly:    phi X174 bacteriophage from synthetic oligonucleotides. Proc. Natl.    Acad. Sci. U. S. A., 100, 15440-15445.-   2. Gibson, D. G., Glass, J. I., Lartigue, C., Noskov, V. N.,    Chuang, R. Y., Algire, M. A., Benders, G. A., Montague, M. G., Ma,    L., Moodie, M. M. et al. (2010) Creation of a Bacterial Cell    Controlled by a Chemically Synthesized Genome. Science, 329, 52-56.-   3. Ellis, H. M., Yu, D. G., DiTizio, T. and Court, D. L. (2001) High    efficiency mutagenesis, repair, and engineering of chromosomal DNA    using single-stranded oligonucleotides. Proc. Natl. Acad. Sci. U. S.    A., 98, 6742-6746.-   4. Wang, H. H., Isaacs, F. J., Carr, P.A., Sun, Z. Z., Xu, G.,    Forest, C. R. and Church, G. M. (2009) Programming cells by    multiplex genome engineering and accelerated evolution. Nature, 460,    894-898.-   5. Isaacs, F. J., Carr, P. A., Wang, H. H., Lajoie, M. J., Sterling,    B., Kraal, L., Tolonen, A. C., Gianoulis, T. A., Goodman, D. B.,    Reppas, N. B. et al. (2011) Precise manipulation of chromosomes in    vivo enables genome-wide codon replacement. Science, 333, 348-353.-   6. Li, X. T., Costantino, N., Lu, L. Y., Liu, D. P., Watt, R. M.,    Cheah, K. S., Court, D. L. and Huang, J. D. (2003) Identification of    factors influencing strand bias in oligonucleotide-mediated    recombination in Escherichia coli. Nucleic Acids Res, 31, 6674-6687.-   7. Wang, H. H., Xu, G., Vonner, A. J. and Church, G. M. (2011)    Modified bases enable high-efficiency oligonucleotide-mediated    allelic replacement via mismatch repair evasion. Nucleic Acids Res,    39, 7336-7347.-   8. Costantino, N. and Court, D. L. (2003) Enhanced levels of lambda    Red-mediated recombinants in mismatch repair mutants. Proc Natl Acad    Sci USA, 100, 15748-15753.-   9. Carr, P. A., Wang, H. H., Sterling, B., Isaacs, F. J., Lajoie, M.    J., Xu, G., Church, G. M. and Jacobson, J. M. (2012) Enhanced    Multiplex Genome Engineering through Cooperative Oligonucleotide    Co-selection. Nucleic Acids Res., 1-11.-   10. Wang, H. H., Kim, H., Cong, L., Jeong, J., Bang, D. and    Church, G. M. (2012) Genome-scale promoter engineering by    coselection MAGE. Nat Meth, 9, 591-593.-   11. Zechner, E. L., Wu, C. A. and Marians, K. J. (1992) Coordinated    leading- and lagging-strand synthesis at the Escherichia coli DNA    replication fork. II. Frequency of primer synthesis and efficiency    of primer utilization control Okazaki fragment size. Journal of    Biological Chemistry, 267, 4045-4053.-   12. Tougu, K. and Marians, K. J. (1996) The Extreme C Terminus of    Primase Is Required for Interaction with DnaB at the Replication    Fork. Journal of Biological Chemistry, 271, 21391-21397.-   13. Tougu, K. and Marians, K. J. (1996) The Interaction between    Helicase and Primase Sets the Replication Fork Clock. Journal of    Biological Chemistry, 271, 21398-21405.-   14. DeVito, J. A. (2008) Recombineering with tolC as a    selectable/counter-selectable marker: remodeling the rRNA operons of    Escherichia coli. Nucleic Acids Res, 36, e4.-   15. Mosberg, J. A., Lajoie, M. J. and Church, G. M. (2010) Lambda    Red Recombineering in Escherichia coli Occurs Through a Fully    Single-Stranded Intermediate. Genetics, 186, 791-799.-   16. Maresca, M., Erler, A., Fu, J., Friedrich, A., Zhang, Y. M. and    Stewart, A. F. (2010) Single-stranded heteroduplex intermediates in    lambda Red homologous recombination. BMC Mol. Biol., 11.-   17. Wang, H. H. and Church, G. M. (2011) Multiplexed genome    engineering and genotyping methods applications for synthetic    biology and metabolic engineering. Methods Enzymol, 498, 409-426.-   18. Jekel, J. F., Katz, D. L., Elmore, J. G. and Wild, D. (2001)    Epidemiology, Biostatistics, & Preventative Medicine. W. B.    Saunders.-   19. Erler, A., Wegmann, S., Elie-Caille, C., Bradshaw, C. R.,    Maresca, M., Seidel, R., Habermann, B., Muller, D. J. and    Stewart, A. F. (2009) Conformational Adaptability of Red beta during    DNA Annealing and Implications for Its Structural Relationship with    Rad52. J. Mol. Biol., 391, 586-598.-   20. Posfai, G., Plunkett, G., Feher, T., Frisch, D., Keil, G. M.,    Umenhoffer, K., Kolisnychenko, V., Stahl, B., Sharma, S. S., de    Arruda, M. et al. (2006) Emergent properties of reduced-genome    Escherichia coli. Science, 312, 1044-1046.-   21. Blomfield, I. C., Vaughn, V., Rest, R. F. and    Eisenstein, B. I. (1991) Allelic exchange in Escherichia coli using    the Bacillus subtilis sacB gene and a temperature-sensitive pSC101    replicon. Mol. Microbiol., 5, 1447-1457.-   22. Warming, S., Costantino, N., Court, D. L., Jenkins, N. A. and    Copeland, N. G. (2005) Simple and highly efficient BAC    recombineering using galK selection. Nucleic Acids Res., 33, e36.-   23. Tashiro, Y., Fukutomi, H., Terakubo, K., Saito, K. and    Umeno, D. (2011) A nucleoside kinase as a dual selector for genetic    switches and circuits. Nucleic Acids Res., 39, e12.-   24. Oakley, A. J., Loscha, K. V., Schaeffer, P. M., Liepinsh, E.,    Pintacuda, G., Wilce, M. C. J., Otting, G. and Dixon, N. E. (2005)    Crystal and Solution Structures of the Helicase-binding Domain of    Escherichia coli Primase. Journal of Biological Chemistry, 280,    11495-11504.-   25. Corn, J. E. and Berger, J. M. (2006) Regulation of bacterial    priming and daughter strand synthesis through helicase-primase    interactions. Nucleic Acids Res., 34, 4082-4088.-   26. Lia, G., Michel, B. and Allemand, J. F. (2012) Polymerase    Exchange During Okazaki Fragment Synthesis Observed in Living Cells.    Science, 335, 328-331.-   27. Tanner, N. A., Hamdan, S. M., Jergic, S., Loscha, K. V.,    Schaeffer, P. M., Dixon, N. E. and van Oijen, A.M. (2008)    Single-molecule studies of fork dynamics in Escherichia coli DNA    replication. Nat Struct Mol Biol, 15, 170-176.-   28. Nakayama, M. and Ohara, O. (2005) Improvement of recombination    efficiency by mutation of Red proteins. Biotechniques, 38, 917-924.-   29. Yao, N. Y., Georgescu, R. E., Finkelstein, J. and    O'Donnell, M. E. (2009) Single-molecule analysis reveals that the    lagging strand increases replisome processivity but slows    replication fork progression. Proceedings of the National Academy of    Sciences, 106, 13236-13241.-   30. Rybalchenko, N., Golub, E. I., Bi, B. and Radding, C. M. (2004)    Strand invasion promoted by recombination protein β of coliphage λ.    Proc. Natl. Acad. Sci. U. S. A., 101, 17056-17060.-   31. Asai, T. and Kogoma, T. (1994) D-loops and R-loops: alternative    mechanisms for the initiation of chromosome replication in    Escherichia coli. Journal of Bacteriology, 176, 1807-1812.-   32. Okazaki, R., Okazaki, T., Sakabe, K., Sugimoto, K. and    Sugino, A. (1968) Mechanism of DNA chain growth. I. Possible    discontinuity and unusual secondary structure of newlysynthesized    chains. Proceedings of the National Academy of Sciences, 59,    598-605.

EQUIVALENTS

Other embodiments will be evident to those of skill in the art. Itshould be understood that the foregoing description is provided forclarity only and is merely exemplary. The spirit and scope of thepresent invention are not limited to the above example, but areencompassed by the claims. All publications, patents and patentapplications cited above are incorporated by reference herein in theirentirety for all purposes to the same extent as if each individualpublication or patent application were specifically indicated to be soincorporated by reference.

What is claimed is:
 1. A method of introducing a nucleic acid sequenceinto the genome of a cell, wherein the cell has impaired or inhibited ordisrupted DnaG primase activity, or impaired or inhibited or disruptedDnaB helicase activity, or larger or increased gaps or distance betweenOkazaki fragments or lowered or reduced frequency of Okazaki fragmentinitiation, or the cell has increased single stranded DNA (ssDNA) on thelagging strand of the replication fork comprising transforming the cellwith a nucleic acid oligomer, wherein the nucleic acid oligomer isintroduced into the genome of the cell through recombination, andwherein the nucleic acid oligomer is single-stranded DNA.
 2. The methodof claim 1, wherein the cell is transformed with multiple nucleic acidoligomers.
 3. The method of claim 1, wherein multiple mutations aregenerated in a chromosome of the cell through recombination.
 4. Themethod of claim 1, wherein multiple mutations are generated in thegenome of the cell through recombination.
 5. The method of claim 1,wherein the cell is contacted with a pool of nucleic acid oligomers. 6.The method of claim 1, wherein the cell is deficient in at least onenuclease.
 7. The method of claim 1, wherein the cell is grown into apopulation of cells having impaired or inhibited or disrupted DnaGprimase activity or impaired or inhibited or disrupted DnaB helicaseactivity, or larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragmentinitiation, or the cell has increased single stranded DNA (ssDNA) on thelagging strand of the replication fork and the population of cells istransformed with at least one nucleic acid oligomer.
 8. The method ofclaim 1, wherein the cell is grown into a population of cells havingimpaired or inhibited or disrupted DnaG primase activity or impaired orinhibited or disrupted DnaB helicase activity, or larger or increasedgaps or distance between Okazaki fragments or lowered or reducedfrequency of Okazaki fragment initiation, or the cell has increasedsingle stranded DNA (ssDNA) on the lagging strand of the replicationfork and the population of cells is transformed with at least onenucleic acid oligomer and the steps of growing and transforming arerepeated until a plurality of nucleic acid sequences have beenintroduced into the cells.
 9. A method of serially introducing a nucleicacid sequence into the genome of a cell wherein the cell has impaired orinhibited or disrupted DnaG primase activity or impaired or inhibited ordisrupted DnaB helicase activity, or larger or increased gaps ordistance between Okazaki fragments or lowered or reduced frequency ofOkazaki fragment initiation, or the cell has increased single strandedDNA (ssDNA) on the lagging strand of the replication fork comprisingtransforming the cell with a nucleic acid oligomer two or more times,wherein the nucleic acid oligomer is introduced into the genome of thecell through recombination, and wherein the nucleic acid oligomer issingle-stranded DNA.
 10. The method of claim 9, wherein the cell istransformed with multiple nucleic acid oligomers.
 11. The method ofclaim 9, wherein multiple mutations are generated in a chromosome of thecell through recombination.
 12. The method of claim 9, wherein multiplemutations are generated in the genome of the cell through recombination.13. The method of claim 9, wherein the cell is contacted with a pool ofnucleic acid oligomers.
 14. The method of claim 9, wherein the cell isdeficient in at least one nuclease.
 15. The method of claim 9, whereinthe cell is grown into a population of cells having impaired orinhibited or disrupted DnaG primase activity or impaired or inhibited ordisrupted DnaB helicase activity, or larger or increased gaps ordistance between Okazaki fragments or lowered or reduced frequency ofOkazaki fragment initiation, or the cell has increased single strandedDNA (ssDNA) on the lagging strand of the replication fork and thepopulation of cells is transformed with at least one nucleic acidoligomer.
 16. The method of claim 9, wherein the cell is grown into apopulation of cells having impaired or inhibited or disrupted DnaGprimase activity or impaired or inhibited or disrupted DnaB helicaseactivity, or larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragmentinitiation, or the cell has increased single stranded DNA (ssDNA) on thelagging strand of the replication fork and the population of cells istransformed with at least one nucleic acid oligomer and the steps ofgrowing and transforming are repeated until a plurality of nucleic acidsequences have been introduced into the cells.
 17. A method ofintroducing a nucleic acid sequence into the genome of a cell whereinthe cell has impaired or inhibited or disrupted DnaG primase activity orimpaired or inhibited or disrupted DnaB helicase activity, or larger orincreased gaps or distance between Okazaki fragments or lowered orreduced frequency of Okazaki fragment initiation, or the cell hasincreased single stranded DNA (ssDNA) on the lagging strand of thereplication fork and is deficient in at least one nuclease comprisingtransforming the cell with a nucleic acid oligomer, wherein the nucleicacid oligomer is introduced into the genome of the cell throughrecombination, and wherein the nucleic acid oligomer is single-strandedDNA.
 18. The method of claim 17, wherein a plurality of exogenousnucleic acid sequences are introduced through recombination into thegenome of the cells having impaired or inhibited or disrupted DnaGprimase activity or impaired or inhibited or disrupted DnaB helicaseactivity, or larger or increased gaps or distance between Okazakifragments or lowered or reduced frequency of Okazaki fragmentinitiation, or the cell has increased single stranded DNA (ssDNA) on thelagging strand of the replication fork and being deficient in at leastone nuclease.